<?xml version="1.0" encoding="UTF-8"?>
<GoldLabel drug="PREMARIN">
  <Text>
    <Section id="S1" name="adverse reactions">  6 ADVERSE REACTIONS

  The following serious adverse reactions are discussed elsewhere in labeling:

 *   Cardiovascular Disorders  [see  Boxed Warning  ,  Warnings and Precautions (5.1)  ]  
 *   Malignant Neoplasms  [see  Boxed Warning  ,  Warnings and Precautions (5.2)  ]  
      EXCERPT:   Most common adverse reactions (&gt;= 5 percent) are: abdominal pain, asthenia, pain, back pain, headache, flatulence, nausea, depression, insomnia, breast pain, endometrial hyperplasia, leucorrhea, vaginal hemorrhage, and vaginitis. (  6.1  )
 

   To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch    

 

  6.1 Clinical Study Experience

  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

 During the first year of a 2-year clinical trial with 2,333 postmenopausal women with a uterus between 40 and 65 years of age (88 percent Caucasian), 1,012 women were treated with conjugated estrogens, and 332 were treated with placebo.

 Table 1 summarizes treatment-related adverse reactions that occurred at a rate of &gt;= 1 percent in any treatment group.

 Table 1: TREATMENT RELATED ADVERSE REACTIONS AT A FREQUENCY &gt;= 1 PERCENT 
                                           PREMARIN0.625 mg(n=348)  PREMARIN0.45 mg (n=338)  PREMARIN0.3 mg(n=326)  Placebo(n=332)    
  
 Body as a whole                                                                                                
   Abdominal pain                          38 (11)          28 (8)           30 (9)           21 (6)            
   Asthenia                                16 (5)           8 (2)            14 (4)           3 (1)             
   Back pain                               18 (5)           11 (3)           13 (4)           4 (1)             
   Chest pain                              2 (1)            3 (1)            4 (1)            2 (1)             
   Generalized edema                       7 (2)            6 (2)            4 (1)            8 (2)             
   Headache                                45 (13)          47 (14)          44 (13)          46 (14)           
   Moniliasis                              5 (1)            4 (1)            4 (1)            1 (0)             
   Pain                                    17 (5)           10 (3)           12 (4)           14 (4)            
   Pelvic pain                             10 (3)           9 (3)            8 (2)            4 (1)             
 Cardiovascular system                                                                                          
   Hypertension                            4 (1)            4 (1)            7 (2)            5 (2)             
   Migraine                                7 (2)            1 (0)            0                3 (1)             
   Palpitation                             3 (1)            3 (1)            3 (1)            4 (1)             
   Vasodilatation                          2 (1)            2 (1)            3 (1)            5 (2)             
 Digestive system                                                                                               
   Constipation                            7 (2)            6 (2)            4 (1)            3 (1)             
   Diarrhea                                4 (1)            5 (1)            5 (2)            8 (2)             
   Dyspepsia                               7 (2)            5 (1)            6 (2)            14 (4)            
   Eructation                              1 (0)            1 (0)            4 (1)            1 (0)             
   Flatulence                              22 (6)           18 (5)           13 (4)           8 (2)             
   Increased appetite                      4 (1)            1 (0)            1 (0)            2 (1)             
   Nausea                                  16 (5)           10 (3)           15 (5)           16 (5)            
 Metabolic and nutritional                                                                                      
   Hyperlipidemia                          2 (1)            4 (1)            3 (1)            2 (1)             
   Peripheral edema                        5 (1)            2 (1)            4 (1)            3 (1)             
   Weight gain                             11 (3)           10 (3)           8 (2)            14 (4)            
 Musculoskeletal system                                                                                         
   Arthralgia                              6 (2)            3 (1)            2 (1)            5 (2)             
   Leg cramps                              10 (3)           5 (1)            9 (3)            4 (1)             
   Myalgia                                 2 (1)            1 (0)            4 (1)            1 (0)             
 Nervous system                                                                                                 
   Anxiety                                 6 (2)            4 (1)            2 (1)            4 (1)             
   Depression                              17 (5)           15 (4)           10 (3)           17 (5)            
   Dizziness                               9 (3)            7 (2)            4 (1)            5 (2)             
   Emotional lability                      3 (1)            4 (1)            5 (2)            8 (2)             
   Hypertonia                              1 (0)            1 (0)            5 (2)            3 (1)             
   Insomnia                                16 (5)           10 (3)           13 (4)           14 (4)            
   Nervousness                             9 (3)            12 (4)           2 (1)            6 (2)             
 Skin and appendages                                                                                            
   Acne                                    3 (1)            1 (0)            8 (2)            3 (1)             
   Alopecia                                6 (2)            6 (2)            5 (2)            2 (1)             
   Hirsutism                               4 (1)            2 (1)            1 (0)            0                 
   Pruritus                                11 (3)           11 (3)           10 (3)           3 (1)             
   Rash                                    6 (2)            3 (1)            1 (0)            2 (1)             
   Skin discoloration                      4 (1)            2 (1)            0                1 (0)             
   Sweating                                4 (1)            1 (0)            3 (1)            4 (1)             
 Urogenital system                                                                                              
   Breast disorder                         6 (2)            3 (1)            3 (1)            6 (2)             
   Breast enlargement                      3 (1)            4 (1)            7 (2)            3 (1)             
   Breast neoplasm                         4 (1)            4 (1)            7 (2)            7 (2)             
   Breast pain                             37 (11)          39 (12)          24 (7)           26 (8)            
   Cervix disorder                         8 (2)            4 (1)            5 (2)            0                 
   Dysmenorrhea                            12 (3)           10 (3)           4 (1)            2 (1)             
   Endometrial disorder                    4 (1)            2 (1)            2 (1)            0                 
   Endometrial hyperplasia                 16 (5)           8 (2)            1 (0)            0                 
   Leukorrhea                              17 (5)           17 (5)           12 (4)           6 (2)             
   Metrorrhagia                            11 (3)           4 (1)            3 (1)            1 (0)             
   Urinary tract infection                 1 (0)            2 (1)            1 (0)            4 (1)             
   Uterine fibroids enlarged               6 (2)            1 (0)            2 (1)            2 (1)             
   Uterine spasm                           11 (3)           5 (1)            3 (1)            2 (1)             
   Vaginal dryness                         1 (0)            2 (1)            1 (0)            6 (2)             
   Vaginal hemorrhage                      46 (13)          13 (4)           6 (2)            0                 
   Vaginal moniliasis                      14 (4)           10 (3)           12 (4)           5 (2)             
   Vaginitis                               18 (5)           7 (2)            9 (3)            1 (0)             
             6.2 Postmarketing Experience
   The following additional adverse reactions have been identified during post-approval use of PREMARIN. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible always to reliably estimate their frequency or establish a causal relationship to drug exposure.

     Genitourinary system  

 Abnormal uterine bleeding; dysmenorrheal or pelvic pain, increase in size of uterine leiomyomata, vaginitis, including vaginal candidiasis, change in cervical secretion, ovarian cancer, endometrial hyperplasia, endometrial cancer, leukorrhea.

     Breasts  

 Tenderness, enlargement, pain, discharge, galactorrhea, fibrocystic breast changes, breast cancer, gynecomastia in males.

     Cardiovascular  

 Deep and superficial venous thrombosis, pulmonary embolism, thrombophlebitis, myocardial infarction, stroke, increase in blood pressure.

     Gastrointestinal  

 Nausea, vomiting, abdominal pain, bloating, cholestatic jaundice, increased incidence of gallbladder disease, pancreatitis, enlargement of hepatic hemangiomas, ischemic colitis.

     Skin  

 Chloasma or melasma that may persist when drug is discontinued, erythema multiforme, erythema nodosum, loss of scalp hair, hirsutism, pruritus, rash.

     Eyes  

 Retinal vascular thrombosis, intolerance to contact lenses.

     Central nervous system  

 Headache, migraine, dizziness , mental depression, nervousness, mood disturbances, irritability, exacerbation of epilepsy, dementia, possible growth potentiation of benign meningioma.

     Miscellaneous  

 Increase or decrease in weight, glucose intolerance, aggravation of porphyria, edema, arthralgias, leg cramps, changes in libido, urticaria, exacerbation of asthma, increased triglycerides, hypersensitivity.

</Section>
    <Section id="S2" name="boxed warnings">

    BOXED WARNING: WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA

    WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA  

  EXCERPT:   WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA

   See full prescribing information for complete boxed warning.  

   Estrogen-Alone Therapy  

 *  There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens (5.2) 
 *  Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia (5.1, 5.3) 
 *  Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) (5.1) 
 *  The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older (5.3) 
      Estrogen Plus Progestin Therapy  
 

 *  Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia (5.1, 5.3) 
 *  The WHI estrogen plus progestin substudy reported increased risks of stroke, DVT, pulmonary embolism (PE), and myocardial infarction (MI) (5.1) 
 *  The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer (5.2) 
 *  The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older (5.3) 
    
 

    Estrogen-Alone Therapy  

     Endometrial Cancer  

   There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding   [see   Warnings and Precautions (5.2)  ].    

     Cardiovascular Disorders and Probable Dementia  

   Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia   [see   Warnings and Precautions (5.1,     5.3)  , and   Clinical Studies (14.5,     14.6)  ]  .  

   The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg]-alone, relative to placebo  [see   Warnings and Precautions (5.1)  , and   Clinical Studies (14.5)  ].    

   The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women   [see   Warnings and Precautions (5.3)  ,   Use in Specific Populations (8.5)  , and   Clinical Studies (14.6)  ]  .  

   In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens.  

   Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.  

     Estrogen Plus Progestin Therapy  

     Cardiovascular Disorders and Probable Dementia  

   Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia   [see   Warnings and Precautions (5.1,     5.3)  , and   Clinical Studies (14.5  ,   14.6)  ].    

   The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo   [see   Warnings and Precautions (5.1),   and   Clinical Studies (14.5)  ]  .  

   The WHIMS estrogen plus progestin ancillary study of the WHI, reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women   [see   Warnings and Precautions (5.3)  ,   Use in Specific Populations (8.5)  , and   Clinical Studies (14.6)  ]  .  

     Breast Cancer  

   The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer   [see   Warnings and Precautions (5.2)  , and   Clinical Studies (14.5)  ].    

   In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA, and other combinations and dosage forms of estrogens and progestins.  

   Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.  

</Section>
    <Section id="S3" name="warnings and precautions">   5 WARNINGS AND PRECAUTIONS

   EXCERPT:    *  Estrogens increase the risk of gallbladder disease (  5.4  ) 
 *  Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice occurs (  5.5  ,  5.6  ,  5.11  ,  5.12  ) 
 *  Monitor thyroid function in women on thyroid replacement therapy (  5.13  ,  5.18  ) 
    
 

   5.1 Cardiovascular Disorders

  An increased risk of stroke and DVT has been reported with estrogen-alone therapy. An increased risk of PE, DVT, stroke and MI has been reported with estrogen plus progestin therapy. Should any of these events occur or be suspected, estrogen with or without progestin therapy should be discontinued immediately.

 Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately.

    Stroke  

 In the WHI estrogen-alone substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years). The increase in risk was demonstrated in year 1 and persisted [see  Clinical Studies (14.5)  ]  . Should a stroke occur or be suspected, estrogen-alone therapy should be discontinued immediately.

 Subgroup analyses of women 50 to 59 years of age suggest no increased risk of stroke for those women receiving CE (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years).  1  

 In the WHI estrogen plus progestin substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women in the same age group receiving placebo (33 versus 25 per 10,000 women-years) [see  Clinical Studies (14.5)  ]  . The increase in risk was demonstrated after the first year and persisted.  1  Should a stroke occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.

    Coronary Heart Disease  

 In the WHI estrogen-alone substudy, no overall effect on coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD death) was reported in women receiving estrogen-alone compared to placebo  2     [see Clinical Studies (14.5)]    .

 Subgroup analyses of women 50 to 59 years of age suggest a statistically non-significant reduction in CHD events (CE [0.625 mg]-alone compared to placebo) in women with less than 10 years since menopause (8 versus 16 per 10,000 women-years).  1  

 In the WHI estrogen plus progestin substudy, there was a statistically non-significant increased risk of CHD events reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women-years).  1  An increase in relative risk was demonstrated in year 1, and a trend toward decreasing relative risk was reported in years 2 through 5 [see  Clinical Studies (14.5)  ]  .

 In postmenopausal women with documented heart disease (n = 2,763, average 66.7 years of age), in a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study; HERS), treatment with daily CE (0.625 mg) plus MPA (2.5 mg) demonstrated no cardiovascular benefit. During an average follow-up of 4.1 years, treatment with CE plus MPA did not reduce the overall rate of CHD events in postmenopausal women with established CHD. There were more CHD events in the CE plus MPA-treated group than in the placebo group in year 1, but not during the subsequent years. Two thousand, three hundred and twenty-one (2,321) women from the original HERS trial agreed to participate in an open label extension of HERS, HERS II. Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were comparable among women in the CE (0.625 mg) plus MPA (2.5 mg) group and the placebo group in HERS, HERS II, and overall.

    Venous Thromboembolism (VTE)  

 In the WHI estrogen-alone substudy, the risk of VTE (DVT and PE), was increased for women receiving daily CE (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years). The increase in VTE risk was demonstrated during the first 2 years  3   [see  Clinical Studies (14.5)  ]  . Should a VTE occur or be suspected, estrogen-alone therapy should be discontinued immediately.

 In the WHI estrogen plus progestin substudy, a statistically significant 2-fold greater rate of VTE was reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women-years). Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also demonstrated. The increase in VTE risk was demonstrated during the first year and persisted  4   [see  Clinical Studies (14.5)  ]  . Should a VTE occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.

 If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization.

    5.2 Malignant Neoplasms

   Endometrial Cancer  

 An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. The reported endometrial cancer risk among unopposed estrogen users is about 2 to 12 times greater than in non-users, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than 1 year. The greatest risk appears associated with prolonged use, with increased risks of 15- to 24-fold for 5 to 10 years or more, and this risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued.

 Clinical surveillance of all women using estrogen-alone or estrogen plus progestin therapy is important. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestin to postmenopausal estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer.

    Breast Cancer  

 The most important randomized clinical trial providing information about breast cancer in estrogen-alone users is the WHI substudy of daily CE (0.625 mg)-alone. In the WHI estrogen-alone substudy, after an average follow-up of 7.1 years, daily CE (0.625 mg)-alone was not associated with an increased risk of invasive breast cancer [relative risk (RR) 0.80]    5   [see  Clinical Studies (14.5)  ]  .

 The most important randomized clinical trial providing information about breast cancer in estrogen plus progestin users is the WHI substudy of daily CE (0.625 mg) plus MPA (2.5 mg). After a mean follow-up of 5.6 years, the estrogen plus progestin substudy reported an increased risk of invasive breast cancer in women who took daily CE plus MPA. In this substudy, prior use of estrogen-alone or estrogen plus progestin therapy was reported by 26 percent of the women. The relative risk of invasive breast cancer was 1.24, and the absolute risk was 41 versus 33 cases per 10,000 women-years, for CE plus MPA compared with placebo.  6  Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 versus 25 cases per 10,000 women-years for CE plus MPA compared with placebo. Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years for CE plus MPA compared with placebo. In the same substudy, invasive breast cancers were larger, were more likely to be node positive, and were diagnosed at a more advanced stage in the CE (0.625 mg) plus MPA (2.5 mg) group compared with the placebo group. Metastatic disease was rare, with no apparent difference between the two groups. Other prognostic factors, such as histologic subtype, grade and hormone receptor status did not differ between the groups [see  Clinical Studies (14.5)  ]  .

 Consistent with the WHI clinical trial, observational studies have also reported an increased risk of breast cancer for estrogen plus progestin therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use. The risk increased with duration of use, and appeared to return to baseline over about 5 years after stopping treatment (only the observational studies have substantial data on risk after stopping). Observational studies also suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen plus progestin therapy as compared to estrogen-alone therapy. However, these studies have not found significant variation in the risk of breast cancer among different estrogen plus progestin combinations, doses, or routes of administration.

 The use of estrogen-alone and estrogen plus progestin has been reported to result in an increase in abnormal mammograms, requiring further evaluation.

 All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results.

    Ovarian Cancer  

  The WHI estrogen plus progestin substudy reported a statistically non-significant increased risk of ovarian cancer. After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE plus MPA versus placebo was 1.58 (95 percent CI 0.77-3.24). The absolute risk for CE plus MPA versus placebo was 4 versus 3 cases per 10,000 women-years.  7    

  A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. The primary analysis, using case-control comparisons, included 12,110 cancer cases from the 17 prospective studies. The relative risks associated with current use of hormonal therapy was 1.41 (95% confidence interval [CI] 1.32 to 1.50); there was no difference in the risk estimates by duration of the exposure (less than 5 years [median of 3 years] vs. greater than 5 years [median of 10 years] of use before the cancer diagnosis). The relative risk associated with combined current and recent use (discontinued use within 5 years before cancer diagnosis) was 1.37 (95% CI 1.27-1.48), and the elevated risk was significant for both estrogen-alone and estrogen plus progestin products. The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown.  

    5.3 Probable Dementia

  In the WHIMS estrogen-alone ancillary study of WHI, a population of 2,947 hysterectomized women 65 to 79 years of age was randomized to daily CE (0.625 mg)-alone or placebo.

 After an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for CE-alone versus placebo was 1.49 (95 percent CI 0.83-2.66). The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years  8   [see  Use in Specific Populations (8.5)  , and  Clinical Studies (14.6)  ]  .

 In the WHIMS estrogen plus progestin ancillary study of WHI, a population of 4,532 postmenopausal women 65 to 79 years of age was randomized to daily CE (0.625 mg) plus MPA (2.5 mg) or placebo. After an average follow-up of 4 years, 40 women in the CE plus MPA group and 21 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for CE plus MPA versus placebo was 2.05 (95 percent CI 1.21-3.48). The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years  8   [see  Use in Specific Populations (8.5)  , and  Clinical Studies (14.6)  ].  

 When data from the two populations in the WHIMS estrogen-alone and estrogen plus progestin ancillary studies were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable dementia was 1.76 (95 percent CI 1.19-2.60). Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women  8   [see  Use in Specific Populations (8.5)  , and  Clinical Studies (14.6)  ]  .

    5.4 Gallbladder Disease

  A 2- to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens has been reported.

    5.5 Hypercalcemia

  Estrogen administration may lead to severe hypercalcemia in patients with breast cancer and bone metastases. If hypercalcemia occurs, use of the drug should be stopped and appropriate measures taken to reduce the serum calcium level.

    5.6 Visual Abnormalities

  Retinal vascular thrombosis has been reported in patients receiving estrogens. Discontinue medication pending examination if there is sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia, or migraine. If examination reveals papilledema or retinal vascular lesions, estrogens should be permanently discontinued.

    5.7 Anaphylactic Reaction and Angioedema

  Cases of anaphylaxis, which developed within minutes to hours after taking PREMARIN and require emergency medical management, have been reported in the postmarketing setting. Skin (hives, pruritis, swollen lips-tongue-face) and either respiratory tract (respiratory compromise) or gastrointestinal tract (abdominal pain, vomiting) involvement has been noted.

 Angioedema involving the tongue, larynx, face, hands, and feet requiring medical intervention has occurred postmarketing in patients taking PREMARIN. If angioedema involves the tongue, glottis, or larynx, airway obstruction may occur. Patients who develop an anaphylactic reaction with or without angioedema after treatment with PREMARIN should not receive PREMARIN again.

    5.8 Addition of a Progestin When a Woman Has Not Had a Hysterectomy

  Studies of the addition of a progestin for 10 or more days of a cycle of estrogen administration or daily with estrogen in a continuous regimen, have reported a lowered incidence of endometrial hyperplasia than would be induced by estrogen treatment alone. Endometrial hyperplasia may be a precursor to endometrial cancer.

 There are, however, possible risks that may be associated with the use of progestins with estrogens compared to estrogen-alone regimens. These include an increased risk of breast cancer.

    5.9 Elevated Blood Pressure

  In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens. In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogen therapy on blood pressure was not seen.

    5.10 Hypertriglyceridemia

  In women with pre-existing hypertriglyceridemia, estrogen therapy may be associated with elevations of plasma triglycerides leading to pancreatitis. Consider discontinuation of treatment if pancreatitis occurs.

    5.11 Hepatic Impairment and/or Past History of Cholestatic Jaundice

  Estrogens may be poorly metabolized in patients with impaired liver function. For women with a history of cholestatic jaundice associated with past estrogen use or with pregnancy, caution should be exercised, and in the case of recurrence, medication should be discontinued.

    5.12 Hypothyroidism

  Estrogen administration leads to increased thyroid-binding globulin (TBG) levels. Women with normal thyroid function can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T4and T3serum concentrations in the normal range. Women dependent on thyroid hormone replacement therapy who are also receiving estrogens may require increased doses of their thyroid replacement therapy. These women should have their thyroid function monitored in order to maintain their free thyroid hormone levels in an acceptable range.

    5.13 Fluid Retention

  Estrogens may cause some degree of fluid retention. Women with conditions that might be influenced by this factor, such as cardiac or renal dysfunction, warrant careful observation when estrogen alone is prescribed.

    5.14 Hypocalcemia

  Estrogen therapy should be used with caution in individuals with hypoparathyroidism as estrogen-induced hypocalcemia may occur.

    5.15 Hereditary Angioedema

  Exogenous estrogens may exacerbate symptoms of angioedema in women with hereditary angioedema.

    5.16 Exacerbation of Endometriosis

  A few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen-alone therapy. For women known to have residual endometriosis post-hysterectomy, the addition of progestin should be considered.

    5.17 Exacerbation of Other Conditions

  Estrogen therapy may cause an exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus erythematosus, and hepatic hemangiomas and should be used with caution in women with these conditions.

    5.18 Laboratory Tests

  Serum follicle stimulating hormone (FSH) and estradiol levels have not been shown to be useful in the management of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal atrophy.

 Laboratory parameters may be useful in guiding dosage for the treatment of hypoestrogenism due to hypogonadism, castration and primary ovarian failure.

    5.19 Drug-Laboratory Test Interactions

  Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.

 Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T4levels (by column or by radioimmunoassay) or T3levels by radioimmunoassay. T3resin uptake is decreased, reflecting the elevated TBG. Free T4and free T3concentrations are unaltered. Women on thyroid replacement therapy may require higher doses of thyroid hormone.

 Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. Free hormone concentrations, such as testosterone and estradiol, may be decreased. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).

 Increased plasma high-density lipoprotein (HDL) and HDL2cholesterol subfraction concentrations, reduced low-density lipoprotein (LDL) cholesterol concentrations, increased triglyceride levels.

 Impaired glucose tolerance.

</Section>
  </Text>
  <IgnoredRegions>
    <IgnoredRegion len="19" name="heading" section="S1" start="2" />
    <IgnoredRegion len="26" name="heading" section="S3" start="3" />
    <IgnoredRegion len="334" name="excerpt" section="S3" start="33" />
    <IgnoredRegion len="94" name="heading" section="S2" start="115" />
    <IgnoredRegion len="1327" name="excerpt" section="S2" start="212" />
    <IgnoredRegion len="391" name="excerpt" section="S1" start="285" />
    <IgnoredRegion len="28" name="heading" section="S3" start="374" />
    <IgnoredRegion len="29" name="heading" section="S1" start="680" />
    <IgnoredRegion len="23" name="heading" section="S3" start="5567" />
    <IgnoredRegion len="28" name="heading" section="S1" start="8918" />
    <IgnoredRegion len="21" name="heading" section="S3" start="11465" />
    <IgnoredRegion len="23" name="heading" section="S3" start="13252" />
    <IgnoredRegion len="17" name="heading" section="S3" start="13424" />
    <IgnoredRegion len="24" name="heading" section="S3" start="13684" />
    <IgnoredRegion len="40" name="heading" section="S3" start="14059" />
    <IgnoredRegion len="67" name="heading" section="S3" start="14842" />
    <IgnoredRegion len="27" name="heading" section="S3" start="15430" />
    <IgnoredRegion len="25" name="heading" section="S3" start="15735" />
    <IgnoredRegion len="67" name="heading" section="S3" start="15980" />
    <IgnoredRegion len="19" name="heading" section="S3" start="16331" />
    <IgnoredRegion len="20" name="heading" section="S3" start="16907" />
    <IgnoredRegion len="17" name="heading" section="S3" start="17152" />
    <IgnoredRegion len="26" name="heading" section="S3" start="17306" />
    <IgnoredRegion len="34" name="heading" section="S3" start="17436" />
    <IgnoredRegion len="37" name="heading" section="S3" start="17749" />
    <IgnoredRegion len="21" name="heading" section="S3" start="18017" />
    <IgnoredRegion len="38" name="heading" section="S3" start="18418" />
  </IgnoredRegions>
  <Mentions>
    <Mention id="M141" len="24" reason="class_effect" section="S1" start="108" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cardiovascular disorder" meddra_llt_id="10007649" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M30" len="19" reason="class_effect" section="S1" start="199" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neoplasm malignant" meddra_llt_id="10028997" meddra_pt="Neoplasm malignant" meddra_pt_id="10028997" />
    </Mention>
    <Mention id="M1" len="14" reason="preexisting_condition_or_risk_factor" section="S1" start="1048" type="Not_AE_Candidate">
      <Normalization meddra_llt="Postmenopause" meddra_llt_id="10051775" meddra_pt="Postmenopause" meddra_pt_id="10051775" />
    </Mention>
    <Mention id="M29" len="15" reason="general_term" section="S1" start="1561" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M31" len="14" reason="from_drug_use" section="S1" start="1676" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M32" len="8" reason="from_drug_use" section="S1" start="1789" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Asthenia" meddra_llt_id="10003549" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M33" len="9" reason="from_drug_use" section="S1" start="1902" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain back" meddra_llt_id="10033380" meddra_pt="Back pain" meddra_pt_id="10003988" />
    </Mention>
    <Mention id="M122" len="10" reason="from_drug_use" section="S1" start="2015" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain chest" meddra_llt_id="10033387" meddra_pt="Chest pain" meddra_pt_id="10008479" />
    </Mention>
    <Mention id="M2" len="17" reason="AE_rate_lteq_placebo" section="S1" start="2128" type="NonOSE_AE">
      <Normalization meddra_llt="Generalized edema" meddra_llt_id="10018112" meddra_pt="Generalised oedema" meddra_pt_id="10018092" />
    </Mention>
    <Mention id="M123" len="8" reason="from_drug_use" section="S1" start="2241" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Headache" meddra_llt_id="10019211" meddra_pt="Headache" meddra_pt_id="10019211" />
    </Mention>
    <Mention id="M34" len="10" reason="from_drug_use" section="S1" start="2354" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Moniliasis" meddra_llt_id="10027825" meddra_pt="Candida infection" meddra_pt_id="10074170" />
    </Mention>
    <Mention id="M124" len="4" reason="from_drug_use" section="S1" start="2467" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain" meddra_llt_id="10033371" meddra_pt="Pain" meddra_pt_id="10033371" />
    </Mention>
    <Mention id="M35" len="11" reason="from_drug_use" section="S1" start="2580" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain pelvic" meddra_llt_id="10033479" meddra_pt="Pelvic pain" meddra_pt_id="10034263" />
    </Mention>
    <Mention id="M15" len="21" reason="general_term" section="S1" start="2691" type="NonOSE_AE">
      <Normalization meddra_llt="Symptoms involving cardiovascular system" meddra_llt_id="10042758" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M125" len="12" reason="from_drug_use" section="S1" start="2806" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M36" len="8" reason="from_drug_use" section="S1" start="2919" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Migraine" meddra_llt_id="10027599" meddra_pt="Migraine" meddra_pt_id="10027599" />
    </Mention>
    <Mention id="M3" len="11" reason="AE_rate_lteq_placebo" section="S1" start="3032" type="NonOSE_AE">
      <Normalization meddra_llt="Palpitation" meddra_llt_id="10033556" meddra_pt="Palpitations" meddra_pt_id="10033557" />
    </Mention>
    <Mention id="M4" len="14" reason="AE_rate_lteq_placebo" section="S1" start="3145" type="NonOSE_AE">
      <Normalization meddra_llt="Vasodilatation" meddra_llt_id="10047141" meddra_pt="Vasodilatation" meddra_pt_id="10047141" />
    </Mention>
    <Mention id="M16" len="16" reason="general_term" section="S1" start="3256" type="NonOSE_AE">
      <Normalization meddra_llt="Symptoms involving digestive system" meddra_llt_id="10042759" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M37" len="12" reason="from_drug_use" section="S1" start="3371" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M5" len="8" reason="AE_rate_lteq_placebo" section="S1" start="3484" type="NonOSE_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M6" len="9" reason="AE_rate_lteq_placebo" section="S1" start="3597" type="NonOSE_AE">
      <Normalization meddra_llt="Dyspepsia-aggravated" meddra_llt_id="10048482" meddra_pt="Dyspepsia" meddra_pt_id="10013946" />
    </Mention>
    <Mention id="M126" len="10" reason="from_drug_use" section="S1" start="3710" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Eructation" meddra_llt_id="10015137" meddra_pt="Eructation" meddra_pt_id="10015137" />
    </Mention>
    <Mention id="M38" len="10" reason="from_drug_use" section="S1" start="3823" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Flatulence" meddra_llt_id="10016766" meddra_pt="Flatulence" meddra_pt_id="10016766" />
    </Mention>
    <Mention id="M39" len="18" reason="from_drug_use" section="S1" start="3936" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Increased appetite" meddra_llt_id="10021654" meddra_pt="Increased appetite" meddra_pt_id="10021654" />
    </Mention>
    <Mention id="M7" len="6" reason="AE_rate_lteq_placebo" section="S1" start="4049" type="NonOSE_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M17" len="25" reason="general_term" section="S1" start="4160" type="NonOSE_AE">
      <Normalization meddra_llt="Metabolic disorder" meddra_llt_id="10058097" meddra_pt="Metabolic disorder" meddra_pt_id="10058097" />
    </Mention>
    <Mention id="M127" len="14" reason="from_drug_use" section="S1" start="4275" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperlipidemia" meddra_llt_id="10020667" meddra_pt="Hyperlipidaemia" meddra_pt_id="10062060" />
    </Mention>
    <Mention id="M40" len="16" reason="from_drug_use" section="S1" start="4388" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Peripheral edema" meddra_llt_id="10034570" meddra_pt="Oedema peripheral" meddra_pt_id="10030124" />
    </Mention>
    <Mention id="M8" len="11" reason="AE_rate_lteq_placebo" section="S1" start="4501" type="NonOSE_AE">
      <Normalization meddra_llt="Weight gain" meddra_llt_id="10047896" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M18" len="22" reason="general_term" section="S1" start="4612" type="NonOSE_AE">
      <Normalization meddra_llt="Musculoskeletal disorder" meddra_llt_id="10048592" meddra_pt="Musculoskeletal disorder" meddra_pt_id="10048592" />
    </Mention>
    <Mention id="M128" len="10" reason="from_drug_use" section="S1" start="4727" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Arthralgia" meddra_llt_id="10003239" meddra_pt="Arthralgia" meddra_pt_id="10003239" />
    </Mention>
    <Mention id="M41" len="10" reason="from_drug_use" section="S1" start="4840" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cramps leg" meddra_llt_id="10011297" meddra_pt="Muscle spasms" meddra_pt_id="10028334" />
    </Mention>
    <Mention id="M42" len="7" reason="from_drug_use" section="S1" start="4953" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myalgia" meddra_llt_id="10028411" meddra_pt="Myalgia" meddra_pt_id="10028411" />
    </Mention>
    <Mention id="M19" len="14" reason="general_term" section="S1" start="5064" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder nervous system" meddra_llt_id="10013242" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M129" len="7" reason="from_drug_use" section="S1" start="5179" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety" meddra_llt_id="10002855" meddra_pt="Anxiety" meddra_pt_id="10002855" />
    </Mention>
    <Mention id="M9" len="10" reason="AE_rate_lteq_placebo" section="S1" start="5292" type="NonOSE_AE">
      <Normalization meddra_llt="Anxiety/depression" meddra_llt_id="10002872" meddra_pt="Depression" meddra_pt_id="10012378" />
    </Mention>
    <Mention id="M43" len="9" reason="from_drug_use" section="S1" start="5405" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M10" len="18" reason="AE_rate_lteq_placebo" section="S1" start="5518" type="NonOSE_AE">
      <Normalization meddra_llt="Emotional lability" meddra_llt_id="10014555" meddra_pt="Affect lability" meddra_pt_id="10054196" />
    </Mention>
    <Mention id="M130" len="10" reason="from_drug_use" section="S1" start="5631" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertonia" meddra_llt_id="10020852" meddra_pt="Hypertonia" meddra_pt_id="10020852" />
    </Mention>
    <Mention id="M131" len="8" reason="from_drug_use" section="S1" start="5744" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M44" len="11" reason="from_drug_use" section="S1" start="5857" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nervousness" meddra_llt_id="10029216" meddra_pt="Nervousness" meddra_pt_id="10029216" />
    </Mention>
    <Mention id="M20" len="19" reason="general_term" section="S1" start="5968" type="NonOSE_AE">
      <Normalization meddra_llt="Skin disorder" meddra_llt_id="10040831" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M132" len="4" reason="from_drug_use" section="S1" start="6083" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Acne" meddra_llt_id="10000496" meddra_pt="Acne" meddra_pt_id="10000496" />
    </Mention>
    <Mention id="M45" len="8" reason="from_drug_use" section="S1" start="6196" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Alopecia" meddra_llt_id="10001760" meddra_pt="Alopecia" meddra_pt_id="10001760" />
    </Mention>
    <Mention id="M46" len="9" reason="from_drug_use" section="S1" start="6309" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hirsutism" meddra_llt_id="10020112" meddra_pt="Hirsutism" meddra_pt_id="10020112" />
    </Mention>
    <Mention id="M47" len="8" reason="from_drug_use" section="S1" start="6422" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pruritus" meddra_llt_id="10037087" meddra_pt="Pruritus" meddra_pt_id="10037087" />
    </Mention>
    <Mention id="M48" len="4" reason="from_drug_use" section="S1" start="6535" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rash" meddra_llt_id="10037844" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M49" len="18" reason="from_drug_use" section="S1" start="6648" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Discoloration skin" meddra_llt_id="10013076" meddra_pt="Skin discolouration" meddra_pt_id="10040829" />
    </Mention>
    <Mention id="M21" len="8" reason="AE_rate_lteq_placebo" section="S1" start="6761" type="NonOSE_AE">
      <Normalization meddra_llt="Sweating" meddra_llt_id="10042661" meddra_pt="Hyperhidrosis" meddra_pt_id="10020642" />
    </Mention>
    <Mention id="M22" len="17" reason="general_term" section="S1" start="6872" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder urogenital" meddra_llt_id="10013279" meddra_pt="Urogenital disorder" meddra_pt_id="10046694" />
    </Mention>
    <Mention id="M11" len="15" reason="AE_rate_lteq_placebo" section="S1" start="6987" type="NonOSE_AE">
      <Normalization meddra_llt="Breast disorder" meddra_llt_id="10061021" meddra_pt="Breast disorder" meddra_pt_id="10061021" />
    </Mention>
    <Mention id="M50" len="18" reason="from_drug_use" section="S1" start="7100" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Breast enlargement" meddra_llt_id="10006242" meddra_pt="Breast enlargement" meddra_pt_id="10006242" />
    </Mention>
    <Mention id="M12" len="15" reason="AE_rate_lteq_placebo" section="S1" start="7213" type="NonOSE_AE">
      <Normalization meddra_llt="Neoplasm breast" meddra_llt_id="10028985" meddra_pt="Breast neoplasm" meddra_pt_id="10006279" />
    </Mention>
    <Mention id="M51" len="11" reason="from_drug_use" section="S1" start="7326" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain breast" meddra_llt_id="10033385" meddra_pt="Breast pain" meddra_pt_id="10006298" />
    </Mention>
    <Mention id="M52" len="15" reason="from_drug_use" section="S1" start="7439" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder cervix" meddra_llt_id="10013204" meddra_pt="Cervix disorder" meddra_pt_id="10008351" />
    </Mention>
    <Mention id="M53" len="12" reason="from_drug_use" section="S1" start="7552" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dysmenorrhea" meddra_llt_id="10013934" meddra_pt="Dysmenorrhoea" meddra_pt_id="10013935" />
    </Mention>
    <Mention id="M54" len="20" reason="from_drug_use" section="S1" start="7665" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder endometrial" meddra_llt_id="10013219" meddra_pt="Endometrial disorder" meddra_pt_id="10014753" />
    </Mention>
    <Mention id="M55" len="23" reason="from_drug_use" section="S1" start="7778" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Endometrial hyperplasia" meddra_llt_id="10014755" meddra_pt="Endometrial hyperplasia" meddra_pt_id="10014755" />
    </Mention>
    <Mention id="M56" len="10" reason="from_drug_use" section="S1" start="7891" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Leukorrhea" meddra_llt_id="10024400" meddra_pt="Vaginal discharge" meddra_pt_id="10046901" />
    </Mention>
    <Mention id="M57" len="12" reason="from_drug_use" section="S1" start="8004" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Metrorrhagia" meddra_llt_id="10027514" meddra_pt="Metrorrhagia" meddra_pt_id="10027514" />
    </Mention>
    <Mention id="M13" len="23" reason="AE_rate_lteq_placebo" section="S1" start="8117" type="NonOSE_AE">
      <Normalization meddra_llt="Infection urinary tract" meddra_llt_id="10021872" meddra_pt="Urinary tract infection" meddra_pt_id="10046571" />
    </Mention>
    <Mention id="M58" len="25" reason="from_drug_use" section="S1" start="8230" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Uterine fibroids enlarged" meddra_llt_id="10046786" meddra_pt="Uterine leiomyoma" meddra_pt_id="10046798" />
    </Mention>
    <Mention id="M59" len="13" reason="from_drug_use" section="S1" start="8343" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Spasm uterine" meddra_llt_id="10041404" meddra_pt="Uterine spasm" meddra_pt_id="10046823" />
    </Mention>
    <Mention id="M14" len="15" reason="AE_rate_lteq_placebo" section="S1" start="8456" type="NonOSE_AE">
      <Normalization meddra_llt="Dryness vaginal" meddra_llt_id="10013796" meddra_pt="Vulvovaginal dryness" meddra_pt_id="10047791" />
    </Mention>
    <Mention id="M60" len="18" reason="from_drug_use" section="S1" start="8569" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hemorrhage vaginal" meddra_llt_id="10019593" meddra_pt="Vaginal haemorrhage" meddra_pt_id="10046910" />
    </Mention>
    <Mention id="M61" len="18" reason="from_drug_use" section="S1" start="8682" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Moniliasis vaginal" meddra_llt_id="10027839" meddra_pt="Vulvovaginal candidiasis" meddra_pt_id="10047784" />
    </Mention>
    <Mention id="M62" len="9" reason="from_drug_use" section="S1" start="8795" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vaginitis" meddra_llt_id="10046950" meddra_pt="Vaginal infection" meddra_pt_id="10046914" />
    </Mention>
    <Mention id="M23" len="20" reason="general_term" section="S1" start="9260" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder urogenital" meddra_llt_id="10013279" meddra_pt="Urogenital disorder" meddra_pt_id="10046694" />
    </Mention>
    <Mention id="M63" len="25" reason="from_drug_use" section="S1" start="9285" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Uterine bleeding" meddra_llt_id="10046765" meddra_pt="Uterine haemorrhage" meddra_pt_id="10046788" />
    </Mention>
    <Mention id="M64" len="13,4" reason="from_drug_use" section="S1" start="9312,9336" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dysmenorrhoea" meddra_llt_id="10013935" meddra_pt="Dysmenorrhoea" meddra_pt_id="10013935" />
    </Mention>
    <Mention id="M133" len="11" reason="from_drug_use" section="S1" start="9329" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain pelvic" meddra_llt_id="10033479" meddra_pt="Pelvic pain" meddra_pt_id="10034263" />
    </Mention>
    <Mention id="M65" len="39" reason="from_drug_use" section="S1" start="9342" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Degeneration of uterine fibroid" meddra_llt_id="10012158" meddra_pt="Uterine leiomyoma" meddra_pt_id="10046798" />
    </Mention>
    <Mention id="M66" len="9" reason="from_drug_use" section="S1" start="9383" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vaginitis" meddra_llt_id="10046950" meddra_pt="Vaginal infection" meddra_pt_id="10046914" />
    </Mention>
    <Mention id="M67" len="19" reason="from_drug_use" section="S1" start="9404" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vaginal candidiasis" meddra_llt_id="10046898" meddra_pt="Vulvovaginal candidiasis" meddra_pt_id="10047784" />
    </Mention>
    <Mention id="M68" len="28" reason="from_drug_use" section="S1" start="9425" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cervical discharge" meddra_llt_id="10008260" meddra_pt="Cervical discharge" meddra_pt_id="10008260" />
    </Mention>
    <Mention id="M69" len="14" reason="from_drug_use" section="S1" start="9455" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ovarian cancer" meddra_llt_id="10033128" meddra_pt="Ovarian cancer" meddra_pt_id="10033128" />
    </Mention>
    <Mention id="M70" len="23" reason="from_drug_use" section="S1" start="9471" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Endometrial hyperplasia" meddra_llt_id="10014755" meddra_pt="Endometrial hyperplasia" meddra_pt_id="10014755" />
    </Mention>
    <Mention id="M71" len="18" reason="from_drug_use" section="S1" start="9496" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Endometrial cancer" meddra_llt_id="10014733" meddra_pt="Endometrial cancer" meddra_pt_id="10014733" />
    </Mention>
    <Mention id="M72" len="10" reason="from_drug_use" section="S1" start="9516" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Leukorrhea" meddra_llt_id="10024400" meddra_pt="Vaginal discharge" meddra_pt_id="10046901" />
    </Mention>
    <Mention id="M73" len="22" reason="from_drug_use" section="S1" start="9534" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Breast tenderness" meddra_llt_id="10006313" meddra_pt="Breast tenderness" meddra_pt_id="10006313" />
    </Mention>
    <Mention id="M74" len="7,11" reason="from_drug_use" section="S1" start="9534,9558" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Breast enlargement" meddra_llt_id="10006242" meddra_pt="Breast enlargement" meddra_pt_id="10006242" />
    </Mention>
    <Mention id="M75" len="7,4" reason="from_drug_use" section="S1" start="9534,9571" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain breast" meddra_llt_id="10033385" meddra_pt="Breast pain" meddra_pt_id="10006298" />
    </Mention>
    <Mention id="M76" len="7,9" reason="from_drug_use" section="S1" start="9534,9577" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Breast discharge" meddra_llt_id="10006223" meddra_pt="Breast discharge" meddra_pt_id="10006223" />
    </Mention>
    <Mention id="M77" len="12" reason="from_drug_use" section="S1" start="9588" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Galactorrhea" meddra_llt_id="10017592" meddra_pt="Galactorrhoea" meddra_pt_id="10017600" />
    </Mention>
    <Mention id="M78" len="26" reason="from_drug_use" section="S1" start="9602" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Breast fibrocystic" meddra_llt_id="10006250" meddra_pt="Fibrocystic breast disease" meddra_pt_id="10016621" />
    </Mention>
    <Mention id="M79" len="13" reason="from_drug_use" section="S1" start="9630" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Breast cancer" meddra_llt_id="10006187" meddra_pt="Breast cancer" meddra_pt_id="10006187" />
    </Mention>
    <Mention id="M134" len="12" reason="from_drug_use" section="S1" start="9645" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gynecomastia" meddra_llt_id="10018801" meddra_pt="Gynaecomastia" meddra_pt_id="10018800" />
    </Mention>
    <Mention id="M24" len="14" reason="general_term" section="S1" start="9674" type="NonOSE_AE">
      <Normalization meddra_llt="Instability cardiovascular" meddra_llt_id="10022453" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M80" len="4,17" reason="from_drug_use" section="S1" start="9693,9714" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombosis venous deep" meddra_llt_id="10043642" meddra_pt="Deep vein thrombosis" meddra_pt_id="10051055" />
    </Mention>
    <Mention id="M81" len="29" reason="from_drug_use" section="S1" start="9702" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombosis venous superficial" meddra_llt_id="10043643" meddra_pt="Thrombophlebitis superficial" meddra_pt_id="10043595" />
    </Mention>
    <Mention id="M82" len="18" reason="from_drug_use" section="S1" start="9733" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pulmonary embolism" meddra_llt_id="10037377" meddra_pt="Pulmonary embolism" meddra_pt_id="10037377" />
    </Mention>
    <Mention id="M83" len="16" reason="from_drug_use" section="S1" start="9753" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombophlebitis" meddra_llt_id="10043570" meddra_pt="Thrombophlebitis" meddra_pt_id="10043570" />
    </Mention>
    <Mention id="M84" len="21" reason="from_drug_use" section="S1" start="9771" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myocardial infarction" meddra_llt_id="10028596" meddra_pt="Myocardial infarction" meddra_pt_id="10028596" />
    </Mention>
    <Mention id="M85" len="6" reason="from_drug_use" section="S1" start="9794" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stroke" meddra_llt_id="10042244" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M86" len="26" reason="from_drug_use" section="S1" start="9802" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Transient blood pressure increase" meddra_llt_id="10074450" meddra_pt="Blood pressure increased" meddra_pt_id="10005750" />
    </Mention>
    <Mention id="M25" len="16" reason="general_term" section="S1" start="9836" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M87" len="6" reason="from_drug_use" section="S1" start="9857" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M88" len="8" reason="from_drug_use" section="S1" start="9865" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M89" len="14" reason="from_drug_use" section="S1" start="9875" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M90" len="8" reason="from_drug_use" section="S1" start="9891" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bloating" meddra_llt_id="10005265" meddra_pt="Abdominal distension" meddra_pt_id="10000060" />
    </Mention>
    <Mention id="M91" len="20" reason="from_drug_use" section="S1" start="9901" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cholestatic jaundice" meddra_llt_id="10008640" meddra_pt="Jaundice cholestatic" meddra_pt_id="10023129" />
    </Mention>
    <Mention id="M92" len="19" reason="from_drug_use" section="S1" start="9946" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disease gallbladder" meddra_llt_id="10013103" meddra_pt="Gallbladder disorder" meddra_pt_id="10017626" />
    </Mention>
    <Mention id="M93" len="12" reason="from_drug_use" section="S1" start="9967" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pancreatitis" meddra_llt_id="10033645" meddra_pt="Pancreatitis" meddra_pt_id="10033645" />
    </Mention>
    <Mention id="M94" len="34" reason="from_drug_use" section="S1" start="9981" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hemangioma of liver" meddra_llt_id="10019396" meddra_pt="Haemangioma of liver" meddra_pt_id="10018821" />
    </Mention>
    <Mention id="M95" len="16" reason="from_drug_use" section="S1" start="10017" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ischemic colitis" meddra_llt_id="10023037" meddra_pt="Colitis ischaemic" meddra_pt_id="10009895" />
    </Mention>
    <Mention id="M26" len="4" reason="general_term" section="S1" start="10041" type="NonOSE_AE">
      <Normalization meddra_llt="Skin disorder" meddra_llt_id="10040831" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M96" len="8" reason="from_drug_use" section="S1" start="10050" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Chloasma" meddra_llt_id="10008570" meddra_pt="Chloasma" meddra_pt_id="10008570" />
    </Mention>
    <Mention id="M97" len="7" reason="from_drug_use" section="S1" start="10062" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Melasma" meddra_llt_id="10027161" meddra_pt="Chloasma" meddra_pt_id="10008570" />
    </Mention>
    <Mention id="M98" len="19" reason="from_drug_use" section="S1" start="10114" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Erythema multiforme" meddra_llt_id="10015218" meddra_pt="Erythema multiforme" meddra_pt_id="10015218" />
    </Mention>
    <Mention id="M99" len="16" reason="from_drug_use" section="S1" start="10135" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Erythema nodosum" meddra_llt_id="10015226" meddra_pt="Erythema nodosum" meddra_pt_id="10015226" />
    </Mention>
    <Mention id="M100" len="18" reason="from_drug_use" section="S1" start="10153" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hair loss" meddra_llt_id="10019045" meddra_pt="Alopecia" meddra_pt_id="10001760" />
    </Mention>
    <Mention id="M101" len="9" reason="from_drug_use" section="S1" start="10173" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hirsutism" meddra_llt_id="10020112" meddra_pt="Hirsutism" meddra_pt_id="10020112" />
    </Mention>
    <Mention id="M102" len="8" reason="from_drug_use" section="S1" start="10184" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pruritus" meddra_llt_id="10037087" meddra_pt="Pruritus" meddra_pt_id="10037087" />
    </Mention>
    <Mention id="M103" len="4" reason="from_drug_use" section="S1" start="10194" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rash" meddra_llt_id="10037844" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M27" len="4" reason="general_term" section="S1" start="10206" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder eye" meddra_llt_id="10013221" meddra_pt="Eye disorder" meddra_pt_id="10015916" />
      <Normalization meddra_pt="Ocular toxicity" meddra_pt_id="10061137" />
    </Mention>
    <Mention id="M104" len="27" reason="from_drug_use" section="S1" start="10215" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Retinal vascular thrombosis" meddra_llt_id="10062108" meddra_pt="Retinal vascular thrombosis" meddra_pt_id="10062108" />
    </Mention>
    <Mention id="M135" len="29" reason="from_drug_use" section="S1" start="10244" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Contact lens intolerance" meddra_llt_id="10010804" meddra_pt="Contact lens intolerance" meddra_pt_id="10010804" />
    </Mention>
    <Mention id="M28" len="22" reason="general_term" section="S1" start="10281" type="NonOSE_AE">
      <Normalization meddra_llt="Nervous system disorder, central" meddra_llt_id="10029204" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M105" len="8" reason="from_drug_use" section="S1" start="10308" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Headache" meddra_llt_id="10019211" meddra_pt="Headache" meddra_pt_id="10019211" />
    </Mention>
    <Mention id="M106" len="8" reason="from_drug_use" section="S1" start="10318" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Migraine" meddra_llt_id="10027599" meddra_pt="Migraine" meddra_pt_id="10027599" />
    </Mention>
    <Mention id="M107" len="9" reason="from_drug_use" section="S1" start="10328" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M108" len="17" reason="from_drug_use" section="S1" start="10340" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Depression mental" meddra_llt_id="10012386" meddra_pt="Depression" meddra_pt_id="10012378" />
    </Mention>
    <Mention id="M109" len="11" reason="from_drug_use" section="S1" start="10359" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nervousness" meddra_llt_id="10029216" meddra_pt="Nervousness" meddra_pt_id="10029216" />
    </Mention>
    <Mention id="M110" len="17" reason="from_drug_use" section="S1" start="10372" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Mood altered" meddra_llt_id="10027940" meddra_pt="Mood altered" meddra_pt_id="10027940" />
    </Mention>
    <Mention id="M111" len="12" reason="from_drug_use" section="S1" start="10391" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Irritability" meddra_llt_id="10022998" meddra_pt="Irritability" meddra_pt_id="10022998" />
    </Mention>
    <Mention id="M136" len="24" reason="from_drug_use" section="S1" start="10405" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Epilepsy" meddra_llt_id="10015037" meddra_pt="Epilepsy" meddra_pt_id="10015037" />
    </Mention>
    <Mention id="M112" len="8" reason="from_drug_use" section="S1" start="10431" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dementia" meddra_llt_id="10012267" meddra_pt="Dementia" meddra_pt_id="10012267" />
    </Mention>
    <Mention id="M137" len="40" reason="from_drug_use" section="S1" start="10450" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Meningioma benign" meddra_llt_id="10027192" meddra_pt="Meningioma benign" meddra_pt_id="10027192" />
    </Mention>
    <Mention id="M113" len="8,9" reason="from_drug_use" section="S1" start="10516,10537" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight increase" meddra_llt_id="10047898" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M114" len="18" reason="from_drug_use" section="S1" start="10528" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight decrease" meddra_llt_id="10047893" meddra_pt="Weight decreased" meddra_pt_id="10047895" />
    </Mention>
    <Mention id="M115" len="19" reason="from_drug_use" section="S1" start="10548" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Glucose intolerance" meddra_llt_id="10052426" meddra_pt="Glucose tolerance impaired" meddra_pt_id="10018429" />
    </Mention>
    <Mention id="M138" len="24" reason="from_drug_use" section="S1" start="10569" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Porphyria" meddra_llt_id="10036181" meddra_pt="Porphyria" meddra_pt_id="10036181" />
    </Mention>
    <Mention id="M116" len="5" reason="from_drug_use" section="S1" start="10595" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Edema" meddra_llt_id="10014210" meddra_pt="Oedema" meddra_pt_id="10030095" />
    </Mention>
    <Mention id="M117" len="11" reason="from_drug_use" section="S1" start="10602" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Arthralgia" meddra_llt_id="10003239" meddra_pt="Arthralgia" meddra_pt_id="10003239" />
    </Mention>
    <Mention id="M118" len="10" reason="from_drug_use" section="S1" start="10615" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cramps leg" meddra_llt_id="10011297" meddra_pt="Muscle spasms" meddra_pt_id="10028334" />
    </Mention>
    <Mention id="M139" len="17" reason="from_drug_use" section="S1" start="10627" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Libido disorder" meddra_llt_id="10061221" meddra_pt="Libido disorder" meddra_pt_id="10061221" />
    </Mention>
    <Mention id="M119" len="9" reason="from_drug_use" section="S1" start="10646" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Urticaria" meddra_llt_id="10046735" meddra_pt="Urticaria" meddra_pt_id="10046735" />
    </Mention>
    <Mention id="M140" len="22" reason="from_drug_use" section="S1" start="10657" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Exacerbation of asthma" meddra_llt_id="10015575" meddra_pt="Asthma" meddra_pt_id="10003553" />
    </Mention>
    <Mention id="M120" len="23" reason="from_drug_use" section="S1" start="10681" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Plasma triglycerides increased" meddra_llt_id="10035456" meddra_pt="Blood triglycerides increased" meddra_pt_id="10005839" />
    </Mention>
    <Mention id="M121" len="16" reason="from_drug_use" section="S1" start="10706" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drug hypersensitivity" meddra_llt_id="10013700" meddra_pt="Drug hypersensitivity" meddra_pt_id="10013700" />
      <Normalization meddra_pt="Hypersensitivity" meddra_pt_id="10020751" />
    </Mention>
    <Mention id="M163" len="18" reason="class_effect" section="S2" start="1633" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Endometrial cancer" meddra_llt_id="10014733" meddra_pt="Endometrial cancer" meddra_pt_id="10014733" />
    </Mention>
    <Mention id="M155" len="23" reason="AE_only_as_instruction" section="S2" start="1783" type="NonOSE_AE">
      <Normalization meddra_llt="Endometrial hyperplasia" meddra_llt_id="10014755" meddra_pt="Endometrial hyperplasia" meddra_pt_id="10014755" />
    </Mention>
    <Mention id="M156" len="18" reason="AE_only_as_instruction" section="S2" start="1836" type="NonOSE_AE">
      <Normalization meddra_llt="Endometrial cancer" meddra_llt_id="10014733" meddra_pt="Endometrial cancer" meddra_pt_id="10014733" />
    </Mention>
    <Mention id="M153" len="10" reason="preexisting_condition_or_risk_factor" section="S2" start="1985" type="Not_AE_Candidate">
      <Normalization meddra_llt="Neoplasm malignant" meddra_llt_id="10028997" meddra_pt="Neoplasm malignant" meddra_pt_id="10028997" />
    </Mention>
    <Mention id="M142" len="14" reason="preexisting_condition_or_risk_factor" section="S2" start="1999" type="Not_AE_Candidate">
      <Normalization meddra_llt="Postmenopause" meddra_llt_id="10051775" meddra_pt="Postmenopause" meddra_pt_id="10051775" />
    </Mention>
    <Mention id="M154" len="25" reason="preexisting_condition_or_risk_factor" section="S2" start="2061" type="Not_AE_Candidate">
      <Normalization meddra_llt="Bleeding genital" meddra_llt_id="10005117" meddra_pt="Genital haemorrhage" meddra_pt_id="10061178" />
    </Mention>
    <Mention id="M146" len="22" reason="preexisting_condition_or_risk_factor" section="S2" start="2258" type="Not_AE_Candidate">
      <Normalization meddra_llt="Cardiovascular disease, unspecified" meddra_llt_id="10007648" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M147" len="8" reason="preexisting_condition_or_risk_factor" section="S2" start="2284" type="Not_AE_Candidate">
      <Normalization meddra_llt="Dementia" meddra_llt_id="10012267" meddra_pt="Dementia" meddra_pt_id="10012267" />
    </Mention>
    <Mention id="M164" len="6" reason="class_effect" section="S2" start="2485" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stroke" meddra_llt_id="10042244" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M165" len="25" reason="class_effect" section="S2" start="2496" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Deep vein thrombosis" meddra_llt_id="10051055" meddra_pt="Deep vein thrombosis" meddra_pt_id="10051055" />
    </Mention>
    <Mention id="M143" len="14" reason="preexisting_condition_or_risk_factor" section="S2" start="2526" type="Not_AE_Candidate">
      <Normalization meddra_llt="Postmenopause" meddra_llt_id="10051775" meddra_pt="Postmenopause" meddra_pt_id="10051775" />
    </Mention>
    <Mention id="M166" len="8" reason="class_effect" section="S2" start="2882" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dementia" meddra_llt_id="10012267" meddra_pt="Dementia" meddra_pt_id="10012267" />
    </Mention>
    <Mention id="M148" len="14" reason="preexisting_condition_or_risk_factor" section="S2" start="2894" type="Not_AE_Candidate">
      <Normalization meddra_llt="Postmenopause" meddra_llt_id="10051775" meddra_pt="Postmenopause" meddra_pt_id="10051775" />
    </Mention>
    <Mention id="M144" len="14" reason="preexisting_condition_or_risk_factor" section="S2" start="3077" type="Not_AE_Candidate">
      <Normalization meddra_llt="Postmenopause" meddra_llt_id="10051775" meddra_pt="Postmenopause" meddra_pt_id="10051775" />
    </Mention>
    <Mention id="M149" len="22" reason="preexisting_condition_or_risk_factor" section="S2" start="3726" type="Not_AE_Candidate">
      <Normalization meddra_llt="Cardiovascular disease, unspecified" meddra_llt_id="10007648" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M150" len="8" reason="preexisting_condition_or_risk_factor" section="S2" start="3752" type="Not_AE_Candidate">
      <Normalization meddra_llt="Dementia" meddra_llt_id="10012267" meddra_pt="Dementia" meddra_pt_id="10012267" />
    </Mention>
    <Mention id="M157" len="3" reason="AE_from_drug_interaction" section="S2" start="3934" type="NonOSE_AE">
      <Normalization meddra_llt="DVT" meddra_llt_id="10013877" meddra_pt="Deep vein thrombosis" meddra_pt_id="10051055" />
    </Mention>
    <Mention id="M158" len="22" reason="AE_from_drug_interaction" section="S2" start="3939" type="NonOSE_AE">
      <Normalization meddra_llt="Pulmonary embolism" meddra_llt_id="10037377" meddra_pt="Pulmonary embolism" meddra_pt_id="10037377" />
    </Mention>
    <Mention id="M159" len="6" reason="AE_from_drug_interaction" section="S2" start="3964" type="NonOSE_AE">
      <Normalization meddra_llt="Stroke" meddra_llt_id="10042244" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M160" len="25" reason="AE_from_drug_interaction" section="S2" start="3975" type="NonOSE_AE">
      <Normalization meddra_llt="Myocardial infarction" meddra_llt_id="10028596" meddra_pt="Myocardial infarction" meddra_pt_id="10028596" />
    </Mention>
    <Mention id="M151" len="14" reason="preexisting_condition_or_risk_factor" section="S2" start="4005" type="Not_AE_Candidate">
      <Normalization meddra_llt="Postmenopause" meddra_llt_id="10051775" meddra_pt="Postmenopause" meddra_pt_id="10051775" />
    </Mention>
    <Mention id="M161" len="8" reason="AE_from_drug_interaction" section="S2" start="4385" type="NonOSE_AE">
      <Normalization meddra_llt="Dementia" meddra_llt_id="10012267" meddra_pt="Dementia" meddra_pt_id="10012267" />
    </Mention>
    <Mention id="M152" len="14" reason="preexisting_condition_or_risk_factor" section="S2" start="4397" type="Not_AE_Candidate">
      <Normalization meddra_llt="Postmenopause" meddra_llt_id="10051775" meddra_pt="Postmenopause" meddra_pt_id="10051775" />
    </Mention>
    <Mention id="M145" len="14" reason="preexisting_condition_or_risk_factor" section="S2" start="4599" type="Not_AE_Candidate">
      <Normalization meddra_llt="Postmenopause" meddra_llt_id="10051775" meddra_pt="Postmenopause" meddra_pt_id="10051775" />
    </Mention>
    <Mention id="M162" len="13" reason="AE_from_drug_interaction" section="S2" start="4855" type="NonOSE_AE">
      <Normalization meddra_llt="Breast cancer" meddra_llt_id="10006187" meddra_pt="Breast cancer" meddra_pt_id="10006187" />
    </Mention>
    <Mention id="M369" len="24" reason="from_drug_use" section="S3" start="378" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cardiovascular disorder" meddra_llt_id="10007649" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M279" len="6" reason="class_effect" section="S3" start="427" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stroke" meddra_llt_id="10042244" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M280" len="3" reason="class_effect" section="S3" start="438" type="OSE_Labeled_AE">
      <Normalization meddra_llt="DVT" meddra_llt_id="10013877" meddra_pt="Deep vein thrombosis" meddra_pt_id="10051055" />
    </Mention>
    <Mention id="M206" len="2" reason="AE_from_drug_interaction" section="S3" start="510" type="NonOSE_AE">
      <Normalization meddra_llt="PE" meddra_llt_id="10034191" meddra_pt="Pulmonary embolism" meddra_pt_id="10037377" />
    </Mention>
    <Mention id="M207" len="3" reason="AE_from_drug_interaction" section="S3" start="514" type="NonOSE_AE">
      <Normalization meddra_llt="DVT" meddra_llt_id="10013877" meddra_pt="Deep vein thrombosis" meddra_pt_id="10051055" />
    </Mention>
    <Mention id="M208" len="6" reason="AE_from_drug_interaction" section="S3" start="519" type="NonOSE_AE">
      <Normalization meddra_llt="Stroke" meddra_llt_id="10042244" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M209" len="2" reason="AE_from_drug_interaction" section="S3" start="530" type="NonOSE_AE">
      <Normalization meddra_llt="MI" meddra_llt_id="10027524" meddra_pt="Myocardial infarction" meddra_pt_id="10028596" />
    </Mention>
    <Mention id="M168" len="25" reason="preexisting_condition_or_risk_factor" section="S3" start="737" type="Not_AE_Candidate">
      <Normalization meddra_llt="Generalised arterial disease" meddra_llt_id="10073904" meddra_pt="Arterial disorder" meddra_pt_id="10060963" />
    </Mention>
    <Mention id="M169" len="12" reason="preexisting_condition_or_risk_factor" section="S3" start="777" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M170" len="17" reason="preexisting_condition_or_risk_factor" section="S3" start="791" type="Not_AE_Candidate">
      <Normalization meddra_llt="Diabetes mellitus" meddra_llt_id="10012601" meddra_pt="Diabetes mellitus" meddra_pt_id="10012601" />
    </Mention>
    <Mention id="M198" len="11" reason="preexisting_condition_or_risk_factor" section="S3" start="810" type="Not_AE_Candidate">
      <Normalization meddra_llt="Tobacco use disorder, continuous use" meddra_llt_id="10043907" meddra_pt="Tobacco abuse" meddra_pt_id="10043903" />
    </Mention>
    <Mention id="M171" len="20" reason="preexisting_condition_or_risk_factor" section="S3" start="823" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hypercholesterolemia" meddra_llt_id="10020604" meddra_pt="Hypercholesterolaemia" meddra_pt_id="10020603" />
    </Mention>
    <Mention id="M172" len="7" reason="preexisting_condition_or_risk_factor" section="S3" start="849" type="Not_AE_Candidate">
      <Normalization meddra_llt="Obesity" meddra_llt_id="10029883" meddra_pt="Obesity" meddra_pt_id="10029883" />
    </Mention>
    <Mention id="M167" len="27" reason="preexisting_condition_or_risk_factor" section="S3" start="865" type="Not_AE_Candidate">
      <Normalization meddra_llt="Venous thromboembolism" meddra_llt_id="10066899" meddra_pt="Embolism venous" meddra_pt_id="10014522" />
    </Mention>
    <Mention id="M173" len="3" reason="preexisting_condition_or_risk_factor" section="S3" start="938" type="Not_AE_Candidate">
      <Normalization meddra_llt="Venous thromboembolism" meddra_llt_id="10066899" meddra_pt="Embolism venous" meddra_pt_id="10014522" />
    </Mention>
    <Mention id="M174" len="7" reason="preexisting_condition_or_risk_factor" section="S3" start="943" type="Not_AE_Candidate">
      <Normalization meddra_llt="Obesity" meddra_llt_id="10029883" meddra_pt="Obesity" meddra_pt_id="10029883" />
    </Mention>
    <Mention id="M175" len="28" reason="preexisting_condition_or_risk_factor" section="S3" start="956" type="Not_AE_Candidate">
      <Normalization meddra_llt="Systemic lupus erythematosus" meddra_llt_id="10042945" meddra_pt="Systemic lupus erythematosus" meddra_pt_id="10042945" />
    </Mention>
    <Mention id="M281" len="6" reason="class_effect" section="S3" start="1117" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stroke" meddra_llt_id="10042244" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M210" len="6" reason="AE_only_as_instruction" section="S3" start="1408" type="NonOSE_AE">
      <Normalization meddra_llt="Stroke" meddra_llt_id="10042244" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M211" len="6" reason="AE_rate_lteq_placebo" section="S3" start="1577" type="NonOSE_AE">
      <Normalization meddra_llt="Stroke" meddra_llt_id="10042244" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M212" len="6" reason="AE_from_drug_interaction" section="S3" start="1798" type="NonOSE_AE">
      <Normalization meddra_llt="Stroke" meddra_llt_id="10042244" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M213" len="6" reason="AE_only_as_instruction" section="S3" start="2116" type="NonOSE_AE">
      <Normalization meddra_llt="Stroke" meddra_llt_id="10042244" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M214" len="27" reason="AE_rate_lteq_placebo" section="S3" start="2303" type="NonOSE_AE">
      <Normalization meddra_llt="Coronary heart disease" meddra_llt_id="10068617" meddra_pt="Coronary artery disease" meddra_pt_id="10011078" />
    </Mention>
    <Mention id="M215" len="2" reason="AE_rate_lteq_placebo" section="S3" start="2360" type="NonOSE_AE">
      <Normalization meddra_llt="MI" meddra_llt_id="10027524" meddra_pt="Myocardial infarction" meddra_pt_id="10028596" />
    </Mention>
    <Mention id="M216" len="9" reason="AE_rate_lteq_placebo" section="S3" start="2364" type="NonOSE_AE">
      <Normalization meddra_llt="Silent myocardial infarction" meddra_llt_id="10049768" meddra_pt="Silent myocardial infarction" meddra_pt_id="10049768" />
    </Mention>
    <Mention id="M218" len="9" reason="general_term" section="S3" start="2378" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiac death" meddra_llt_id="10049993" meddra_pt="Cardiac death" meddra_pt_id="10049993" />
    </Mention>
    <Mention id="M217" len="3" reason="AE_rate_lteq_placebo" section="S3" start="2602" type="NonOSE_AE">
      <Normalization meddra_llt="Coronary heart disease" meddra_llt_id="10068617" meddra_pt="Coronary artery disease" meddra_pt_id="10011078" />
    </Mention>
    <Mention id="M205" len="9" reason="preexisting_condition_or_risk_factor" section="S3" start="2694" type="Not_AE_Candidate">
      <Normalization meddra_llt="Menopause" meddra_llt_id="10027308" meddra_pt="Menopause" meddra_pt_id="10027308" />
    </Mention>
    <Mention id="M219" len="3" reason="AE_from_drug_interaction" section="S3" start="2854" type="NonOSE_AE">
      <Normalization meddra_llt="Coronary heart disease" meddra_llt_id="10068617" meddra_pt="Coronary artery disease" meddra_pt_id="10011078" />
    </Mention>
    <Mention id="M176" len="14" reason="preexisting_condition_or_risk_factor" section="S3" start="3186" type="Not_AE_Candidate">
      <Normalization meddra_llt="Postmenopause" meddra_llt_id="10051775" meddra_pt="Postmenopause" meddra_pt_id="10051775" />
    </Mention>
    <Mention id="M199" len="13" reason="preexisting_condition_or_risk_factor" section="S3" start="3223" type="Not_AE_Candidate">
      <Normalization meddra_llt="Cardiac disorder" meddra_llt_id="10061024" meddra_pt="Cardiac disorder" meddra_pt_id="10061024" />
    </Mention>
    <Mention id="M177" len="22" reason="preexisting_condition_or_risk_factor" section="S3" start="3335" type="Not_AE_Candidate">
      <Normalization meddra_llt="Cardiovascular disease, unspecified" meddra_llt_id="10007648" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M220" len="3" reason="negation" section="S3" start="3611" type="NonOSE_AE">
      <Normalization meddra_llt="Coronary heart disease" meddra_llt_id="10068617" meddra_pt="Coronary artery disease" meddra_pt_id="10011078" />
    </Mention>
    <Mention id="M178" len="14" reason="preexisting_condition_or_risk_factor" section="S3" start="3625" type="Not_AE_Candidate">
      <Normalization meddra_llt="Postmenopause" meddra_llt_id="10051775" meddra_pt="Postmenopause" meddra_pt_id="10051775" />
    </Mention>
    <Mention id="M179" len="3" reason="preexisting_condition_or_risk_factor" section="S3" start="3663" type="Not_AE_Candidate">
      <Normalization meddra_llt="Coronary heart disease" meddra_llt_id="10068617" meddra_pt="Coronary artery disease" meddra_pt_id="10011078" />
    </Mention>
    <Mention id="M221" len="3" reason="AE_from_drug_interaction" section="S3" start="3684" type="NonOSE_AE">
      <Normalization meddra_llt="Coronary heart disease" meddra_llt_id="10068617" meddra_pt="Coronary artery disease" meddra_pt_id="10011078" />
    </Mention>
    <Mention id="M222" len="10" reason="AE_from_drug_interaction" section="S3" start="4056" type="NonOSE_AE">
      <Normalization meddra_llt="Disease coronary artery" meddra_llt_id="10013098" meddra_pt="Coronary artery disease" meddra_pt_id="10011078" />
    </Mention>
    <Mention id="M282" len="3" reason="class_effect" section="S3" start="4279" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Venous thromboembolism" meddra_llt_id="10066899" meddra_pt="Embolism venous" meddra_pt_id="10014522" />
    </Mention>
    <Mention id="M305" len="3" reason="class_effect" section="S3" start="4284" type="OSE_Labeled_AE">
      <Normalization meddra_llt="DVT" meddra_llt_id="10013877" meddra_pt="Deep vein thrombosis" meddra_pt_id="10051055" />
    </Mention>
    <Mention id="M306" len="2" reason="class_effect" section="S3" start="4292" type="OSE_Labeled_AE">
      <Normalization meddra_llt="PE" meddra_llt_id="10034191" meddra_pt="Pulmonary embolism" meddra_pt_id="10037377" />
    </Mention>
    <Mention id="M283" len="3" reason="class_effect" section="S3" start="4452" type="OSE_Labeled_AE">
      <Normalization meddra_llt="DVT" meddra_llt_id="10013877" meddra_pt="Deep vein thrombosis" meddra_pt_id="10051055" />
    </Mention>
    <Mention id="M284" len="3" reason="class_effect" section="S3" start="4544" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Venous thromboembolism" meddra_llt_id="10066899" meddra_pt="Embolism venous" meddra_pt_id="10014522" />
    </Mention>
    <Mention id="M223" len="3" reason="AE_only_as_instruction" section="S3" start="4645" type="NonOSE_AE">
      <Normalization meddra_llt="Venous thromboembolism" meddra_llt_id="10066899" meddra_pt="Embolism venous" meddra_pt_id="10014522" />
    </Mention>
    <Mention id="M224" len="3" reason="AE_from_drug_interaction" section="S3" start="4829" type="NonOSE_AE">
      <Normalization meddra_llt="Venous thromboembolism" meddra_llt_id="10066899" meddra_pt="Embolism venous" meddra_pt_id="10014522" />
    </Mention>
    <Mention id="M225" len="3" reason="AE_from_drug_interaction" section="S3" start="5031" type="NonOSE_AE">
      <Normalization meddra_llt="DVT" meddra_llt_id="10013877" meddra_pt="Deep vein thrombosis" meddra_pt_id="10051055" />
    </Mention>
    <Mention id="M226" len="2" reason="AE_from_drug_interaction" section="S3" start="5077" type="NonOSE_AE">
      <Normalization meddra_llt="PE" meddra_llt_id="10034191" meddra_pt="Pulmonary embolism" meddra_pt_id="10037377" />
    </Mention>
    <Mention id="M227" len="3" reason="AE_from_drug_interaction" section="S3" start="5157" type="NonOSE_AE">
      <Normalization meddra_llt="Venous thromboembolism" meddra_llt_id="10066899" meddra_pt="Embolism venous" meddra_pt_id="10014522" />
    </Mention>
    <Mention id="M228" len="3" reason="AE_only_as_instruction" section="S3" start="5269" type="NonOSE_AE">
      <Normalization meddra_llt="Venous thromboembolism" meddra_llt_id="10066899" meddra_pt="Embolism venous" meddra_pt_id="10014522" />
    </Mention>
    <Mention id="M229" len="15" reason="AE_only_as_instruction" section="S3" start="5498" type="NonOSE_AE">
      <Normalization meddra_llt="Thromboembolism" meddra_llt_id="10043566" meddra_pt="Embolism" meddra_pt_id="10061169" />
    </Mention>
    <Mention id="M370" len="19" reason="from_drug_use" section="S3" start="5571" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neoplasm malignant" meddra_llt_id="10028997" meddra_pt="Neoplasm malignant" meddra_pt_id="10028997" />
    </Mention>
    <Mention id="M285" len="18" reason="class_effect" section="S3" start="5639" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Endometrial cancer" meddra_llt_id="10014733" meddra_pt="Endometrial cancer" meddra_pt_id="10014733" />
    </Mention>
    <Mention id="M286" len="18" reason="class_effect" section="S3" start="5758" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Endometrial cancer" meddra_llt_id="10014733" meddra_pt="Endometrial cancer" meddra_pt_id="10014733" />
    </Mention>
    <Mention id="M276" len="10" reason="AE_only_as_instruction" section="S3" start="6501" type="NonOSE_AE">
      <Normalization meddra_llt="Neoplasm malignant" meddra_llt_id="10028997" meddra_pt="Neoplasm malignant" meddra_pt_id="10028997" />
    </Mention>
    <Mention id="M200" len="14" reason="preexisting_condition_or_risk_factor" section="S3" start="6515" type="Not_AE_Candidate">
      <Normalization meddra_llt="Postmenopause" meddra_llt_id="10051775" meddra_pt="Postmenopause" meddra_pt_id="10051775" />
    </Mention>
    <Mention id="M201" len="16" reason="preexisting_condition_or_risk_factor" section="S3" start="6586" type="Not_AE_Candidate">
      <Normalization meddra_llt="Bleeding genital" meddra_llt_id="10005117" meddra_pt="Genital haemorrhage" meddra_pt_id="10061178" />
    </Mention>
    <Mention id="M267" len="14" reason="AE_only_as_instruction" section="S3" start="6783" type="NonOSE_AE">
      <Normalization meddra_llt="Postmenopausal symptoms" meddra_llt_id="10050903" meddra_pt="Menopausal symptoms" meddra_pt_id="10027304" />
    </Mention>
    <Mention id="M230" len="23" reason="AE_only_as_instruction" section="S3" start="6852" type="NonOSE_AE">
      <Normalization meddra_llt="Endometrial hyperplasia" meddra_llt_id="10014755" meddra_pt="Endometrial hyperplasia" meddra_pt_id="10014755" />
    </Mention>
    <Mention id="M231" len="18" reason="AE_only_as_instruction" section="S3" start="6905" type="NonOSE_AE">
      <Normalization meddra_llt="Endometrial cancer" meddra_llt_id="10014733" meddra_pt="Endometrial cancer" meddra_pt_id="10014733" />
    </Mention>
    <Mention id="M232" len="13" reason="AE_only_as_instruction" section="S3" start="7021" type="NonOSE_AE">
      <Normalization meddra_llt="Breast cancer" meddra_llt_id="10006187" meddra_pt="Breast cancer" meddra_pt_id="10006187" />
    </Mention>
    <Mention id="M233" len="22" reason="negation" section="S3" start="7257" type="NonOSE_AE">
      <Normalization meddra_llt="Breast cancer invasive NOS" meddra_llt_id="10006190" meddra_pt="Invasive breast carcinoma" meddra_pt_id="10075713" />
    </Mention>
    <Mention id="M234" len="13" reason="AE_only_as_instruction" section="S3" start="7424" type="NonOSE_AE">
      <Normalization meddra_llt="Breast cancer" meddra_llt_id="10006187" meddra_pt="Breast cancer" meddra_pt_id="10006187" />
    </Mention>
    <Mention id="M235" len="22" reason="AE_from_drug_interaction" section="S3" start="7637" type="NonOSE_AE">
      <Normalization meddra_llt="Breast cancer invasive NOS" meddra_llt_id="10006190" meddra_pt="Invasive breast carcinoma" meddra_pt_id="10075713" />
    </Mention>
    <Mention id="M236" len="22" reason="AE_from_drug_interaction" section="S3" start="7840" type="NonOSE_AE">
      <Normalization meddra_llt="Breast cancer invasive NOS" meddra_llt_id="10006190" meddra_pt="Invasive breast carcinoma" meddra_pt_id="10075713" />
    </Mention>
    <Mention id="M237" len="22" reason="AE_from_drug_interaction" section="S3" start="8061" type="NonOSE_AE">
      <Normalization meddra_llt="Breast cancer" meddra_llt_id="10006187" meddra_pt="Breast cancer" meddra_pt_id="10006187" />
    </Mention>
    <Mention id="M238" len="22" reason="AE_from_drug_interaction" section="S3" start="8280" type="NonOSE_AE">
      <Normalization meddra_llt="Breast cancer invasive NOS" meddra_llt_id="10006190" meddra_pt="Invasive breast carcinoma" meddra_pt_id="10075713" />
    </Mention>
    <Mention id="M239" len="23" reason="AE_from_drug_interaction" section="S3" start="8442" type="NonOSE_AE">
      <Normalization meddra_llt="Breast cancer invasive NOS" meddra_llt_id="10006190" meddra_pt="Invasive breast carcinoma" meddra_pt_id="10075713" />
    </Mention>
    <Mention id="M307" len="13" reason="class_effect" section="S3" start="8982" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Breast cancer" meddra_llt_id="10006187" meddra_pt="Breast cancer" meddra_pt_id="10006187" />
    </Mention>
    <Mention id="M240" len="13" reason="AE_from_drug_interaction" section="S3" start="9369" type="NonOSE_AE">
      <Normalization meddra_llt="Breast cancer" meddra_llt_id="10006187" meddra_pt="Breast cancer" meddra_pt_id="10006187" />
    </Mention>
    <Mention id="M241" len="13" reason="AE_only_as_instruction" section="S3" start="9576" type="NonOSE_AE">
      <Normalization meddra_llt="Breast cancer" meddra_llt_id="10006187" meddra_pt="Breast cancer" meddra_pt_id="10006187" />
    </Mention>
    <Mention id="M308" len="19" reason="class_effect" section="S3" start="9782" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Mammogram abnormal" meddra_llt_id="10026736" meddra_pt="Mammogram abnormal" meddra_pt_id="10026736" />
    </Mention>
    <Mention id="M242" len="14" reason="AE_from_drug_interaction" section="S3" start="10206" type="NonOSE_AE">
      <Normalization meddra_llt="Ovarian cancer" meddra_llt_id="10033128" meddra_pt="Ovarian cancer" meddra_pt_id="10033128" />
    </Mention>
    <Mention id="M266" len="14" reason="AE_from_drug_interaction" section="S3" start="10285" type="NonOSE_AE">
      <Normalization meddra_llt="Ovarian cancer" meddra_llt_id="10033128" meddra_pt="Ovarian cancer" meddra_pt_id="10033128" />
    </Mention>
    <Mention id="M180" len="19" reason="indication" section="S3" start="10594" type="Not_AE_Candidate">
      <Normalization meddra_llt="Menopausal symptoms" meddra_llt_id="10027304" meddra_pt="Menopausal symptoms" meddra_pt_id="10027304" />
    </Mention>
    <Mention id="M309" len="14" reason="class_effect" section="S3" start="10640" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ovarian cancer" meddra_llt_id="10033128" meddra_pt="Ovarian cancer" meddra_pt_id="10033128" />
    </Mention>
    <Mention id="M277" len="6" reason="AE_only_as_instruction" section="S3" start="10726" type="NonOSE_AE">
      <Normalization meddra_llt="Cancer" meddra_llt_id="10007050" meddra_pt="Neoplasm malignant" meddra_pt_id="10028997" />
    </Mention>
    <Mention id="M243" len="6" reason="AE_only_as_instruction" section="S3" start="11070" type="NonOSE_AE">
      <Normalization meddra_llt="Cancer" meddra_llt_id="10007050" meddra_pt="Neoplasm malignant" meddra_pt_id="10028997" />
    </Mention>
    <Mention id="M244" len="6" reason="AE_only_as_instruction" section="S3" start="11195" type="NonOSE_AE">
      <Normalization meddra_llt="Cancer" meddra_llt_id="10007050" meddra_pt="Neoplasm malignant" meddra_pt_id="10028997" />
    </Mention>
    <Mention id="M268" len="14" reason="AE_only_as_instruction" section="S3" start="11421" type="NonOSE_AE">
      <Normalization meddra_llt="Ovarian cancer" meddra_llt_id="10033128" meddra_pt="Ovarian cancer" meddra_pt_id="10033128" />
    </Mention>
    <Mention id="M287" len="8" reason="class_effect" section="S3" start="11807" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dementia" meddra_llt_id="10012267" meddra_pt="Dementia" meddra_pt_id="10012267" />
    </Mention>
    <Mention id="M288" len="8" reason="class_effect" section="S3" start="11847" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dementia" meddra_llt_id="10012267" meddra_pt="Dementia" meddra_pt_id="10012267" />
    </Mention>
    <Mention id="M289" len="8" reason="class_effect" section="S3" start="11950" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dementia" meddra_llt_id="10012267" meddra_pt="Dementia" meddra_pt_id="10012267" />
    </Mention>
    <Mention id="M202" len="14" reason="preexisting_condition_or_risk_factor" section="S3" start="12201" type="Not_AE_Candidate">
      <Normalization meddra_llt="Postmenopause" meddra_llt_id="10051775" meddra_pt="Postmenopause" meddra_pt_id="10051775" />
    </Mention>
    <Mention id="M245" len="8" reason="AE_from_drug_interaction" section="S3" start="12448" type="NonOSE_AE">
      <Normalization meddra_llt="Dementia" meddra_llt_id="10012267" meddra_pt="Dementia" meddra_pt_id="10012267" />
    </Mention>
    <Mention id="M246" len="8" reason="AE_from_drug_interaction" section="S3" start="12488" type="NonOSE_AE">
      <Normalization meddra_llt="Dementia" meddra_llt_id="10012267" meddra_pt="Dementia" meddra_pt_id="10012267" />
    </Mention>
    <Mention id="M247" len="8" reason="AE_from_drug_interaction" section="S3" start="12594" type="NonOSE_AE">
      <Normalization meddra_llt="Dementia" meddra_llt_id="10012267" meddra_pt="Dementia" meddra_pt_id="10012267" />
    </Mention>
    <Mention id="M310" len="8" reason="class_effect" section="S3" start="12968" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dementia" meddra_llt_id="10012267" meddra_pt="Dementia" meddra_pt_id="10012267" />
    </Mention>
    <Mention id="M181" len="14" reason="preexisting_condition_or_risk_factor" section="S3" start="13143" type="Not_AE_Candidate">
      <Normalization meddra_llt="Postmenopause" meddra_llt_id="10051775" meddra_pt="Postmenopause" meddra_pt_id="10051775" />
    </Mention>
    <Mention id="M290" len="19" reason="class_effect" section="S3" start="13318" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disease gallbladder" meddra_llt_id="10013103" meddra_pt="Gallbladder disorder" meddra_pt_id="10017626" />
    </Mention>
    <Mention id="M203" len="14" reason="preexisting_condition_or_risk_factor" section="S3" start="13359" type="Not_AE_Candidate">
      <Normalization meddra_llt="Postmenopause" meddra_llt_id="10051775" meddra_pt="Postmenopause" meddra_pt_id="10051775" />
    </Mention>
    <Mention id="M291" len="13" reason="class_effect" section="S3" start="13488" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypercalcemia" meddra_llt_id="10020587" meddra_pt="Hypercalcaemia" meddra_pt_id="10020583" />
    </Mention>
    <Mention id="M182" len="13" reason="preexisting_condition_or_risk_factor" section="S3" start="13519" type="Not_AE_Candidate">
      <Normalization meddra_llt="Breast cancer" meddra_llt_id="10006187" meddra_pt="Breast cancer" meddra_pt_id="10006187" />
    </Mention>
    <Mention id="M183" len="15" reason="preexisting_condition_or_risk_factor" section="S3" start="13537" type="Not_AE_Candidate">
      <Normalization meddra_llt="Bone metastases" meddra_llt_id="10005993" meddra_pt="Metastases to bone" meddra_pt_id="10027452" />
    </Mention>
    <Mention id="M248" len="13" reason="AE_only_as_instruction" section="S3" start="13557" type="NonOSE_AE">
      <Normalization meddra_llt="Hypercalcemia" meddra_llt_id="10020587" meddra_pt="Hypercalcaemia" meddra_pt_id="10020583" />
    </Mention>
    <Mention id="M278" len="30" reason="AE_only_as_instruction" section="S3" start="13647" type="NonOSE_AE">
      <Normalization meddra_llt="Calcium serum decreased" meddra_llt_id="10006979" meddra_pt="Blood calcium decreased" meddra_pt_id="10005395" />
    </Mention>
    <Mention id="M361" len="20" reason="from_drug_use" section="S3" start="13688" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Visual impairment" meddra_llt_id="10047571" meddra_pt="Visual impairment" meddra_pt_id="10047571" />
    </Mention>
    <Mention id="M292" len="27" reason="class_effect" section="S3" start="13712" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Retinal vascular thrombosis" meddra_llt_id="10062108" meddra_pt="Retinal vascular thrombosis" meddra_pt_id="10062108" />
    </Mention>
    <Mention id="M249" len="7,14" reason="AE_only_as_instruction" section="S3" start="13853,13873" type="NonOSE_AE">
      <Normalization meddra_llt="Partial visual loss" meddra_llt_id="10065556" meddra_pt="Visual impairment" meddra_pt_id="10047571" />
    </Mention>
    <Mention id="M250" len="23" reason="AE_only_as_instruction" section="S3" start="13864" type="NonOSE_AE">
      <Normalization meddra_llt="Loss of vision" meddra_llt_id="10024881" meddra_pt="Blindness" meddra_pt_id="10005169" />
    </Mention>
    <Mention id="M251" len="9" reason="AE_only_as_instruction" section="S3" start="13910" type="NonOSE_AE">
      <Normalization meddra_llt="Proptosis" meddra_llt_id="10036905" meddra_pt="Exophthalmos" meddra_pt_id="10015683" />
    </Mention>
    <Mention id="M252" len="8" reason="AE_only_as_instruction" section="S3" start="13921" type="NonOSE_AE">
      <Normalization meddra_llt="Diplopia" meddra_llt_id="10013036" meddra_pt="Diplopia" meddra_pt_id="10013036" />
    </Mention>
    <Mention id="M253" len="8" reason="AE_only_as_instruction" section="S3" start="13934" type="NonOSE_AE">
      <Normalization meddra_llt="Migraine" meddra_llt_id="10027599" meddra_pt="Migraine" meddra_pt_id="10027599" />
    </Mention>
    <Mention id="M254" len="11" reason="AE_only_as_instruction" section="S3" start="13967" type="NonOSE_AE">
      <Normalization meddra_llt="Papilledema" meddra_llt_id="10033703" meddra_pt="Papilloedema" meddra_pt_id="10033712" />
    </Mention>
    <Mention id="M255" len="24" reason="AE_only_as_instruction" section="S3" start="13982" type="NonOSE_AE">
      <Normalization meddra_llt="Dilatation vascular retinal" meddra_llt_id="10013011" meddra_pt="Retinal vascular disorder" meddra_pt_id="10038901" />
    </Mention>
    <Mention id="M293" len="11" reason="from_drug_use" section="S3" start="14112" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anaphylaxis" meddra_llt_id="10002218" meddra_pt="Anaphylactic reaction" meddra_pt_id="10002198" />
    </Mention>
    <Mention id="M362" len="4,11" reason="from_drug_use" section="S3" start="14278,14434" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Skin disorder" meddra_llt_id="10040831" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M294" len="5" reason="from_drug_use" section="S3" start="14284" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hives" meddra_llt_id="10020197" meddra_pt="Urticaria" meddra_pt_id="10046735" />
    </Mention>
    <Mention id="M295" len="8" reason="from_drug_use" section="S3" start="14291" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pruritis" meddra_llt_id="10037086" meddra_pt="Pruritus" meddra_pt_id="10037087" />
    </Mention>
    <Mention id="M296" len="12" reason="from_drug_use" section="S3" start="14301" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Swollen lips" meddra_llt_id="10042723" meddra_pt="Lip swelling" meddra_pt_id="10024570" />
    </Mention>
    <Mention id="M311" len="7,6" reason="from_drug_use" section="S3" start="14301,14314" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Swollen tongue" meddra_llt_id="10042727" meddra_pt="Swollen tongue" meddra_pt_id="10042727" />
    </Mention>
    <Mention id="M312" len="7,4" reason="from_drug_use" section="S3" start="14301,14321" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Swollen of face feeling" meddra_llt_id="10042725" meddra_pt="Swelling face" meddra_pt_id="10042682" />
    </Mention>
    <Mention id="M363" len="17,11" reason="from_drug_use" section="S3" start="14338,14434" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Respiratory disorder" meddra_llt_id="10038683" meddra_pt="Respiratory disorder" meddra_pt_id="10038683" />
    </Mention>
    <Mention id="M297" len="22" reason="from_drug_use" section="S3" start="14357" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Airway compromise" meddra_llt_id="10077277" meddra_pt="Obstructive airways disorder" meddra_pt_id="10061877" />
    </Mention>
    <Mention id="M364" len="22,11" reason="from_drug_use" section="S3" start="14384,14434" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M298" len="14" reason="from_drug_use" section="S3" start="14408" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M299" len="8" reason="from_drug_use" section="S3" start="14424" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M300" len="10" reason="from_drug_use" section="S3" start="14464" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Angioedema" meddra_llt_id="10002424" meddra_pt="Angioedema" meddra_pt_id="10002424" />
    </Mention>
    <Mention id="M313" len="10,4" reason="from_drug_use" section="S3" start="14464,14522" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Angioedema" meddra_llt_id="10002424" meddra_pt="Angioedema" meddra_pt_id="10002424" />
    </Mention>
    <Mention id="M365" len="10,5" reason="from_drug_use" section="S3" start="14464,14511" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Angioedema" meddra_llt_id="10002424" meddra_pt="Angioedema" meddra_pt_id="10002424" />
    </Mention>
    <Mention id="M366" len="10,4" reason="from_drug_use" section="S3" start="14464,14505" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Face angioedema" meddra_llt_id="10079442" meddra_pt="Angioedema" meddra_pt_id="10002424" />
    </Mention>
    <Mention id="M367" len="10,6" reason="from_drug_use" section="S3" start="14464,14497" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Angioedema of larynx" meddra_llt_id="10002427" meddra_pt="Angioedema" meddra_pt_id="10002424" />
    </Mention>
    <Mention id="M368" len="10,6" reason="from_drug_use" section="S3" start="14464,14489" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Angioedema" meddra_llt_id="10002424" meddra_pt="Angioedema" meddra_pt_id="10002424" />
    </Mention>
    <Mention id="M257" len="10" reason="AE_only_as_instruction" section="S3" start="14617" type="NonOSE_AE">
      <Normalization meddra_llt="Angioedema" meddra_llt_id="10002424" meddra_pt="Angioedema" meddra_pt_id="10002424" />
    </Mention>
    <Mention id="M269" len="10,6" reason="AE_only_as_instruction" section="S3" start="14617,14641" type="NonOSE_AE">
      <Normalization meddra_llt="Angioedema" meddra_llt_id="10002424" meddra_pt="Angioedema" meddra_pt_id="10002424" />
    </Mention>
    <Mention id="M270" len="10,7" reason="AE_only_as_instruction" section="S3" start="14617,14649" type="NonOSE_AE">
      <Normalization meddra_llt="Angioedema" meddra_llt_id="10002424" meddra_pt="Angioedema" meddra_pt_id="10002424" />
    </Mention>
    <Mention id="M271" len="10,6" reason="AE_only_as_instruction" section="S3" start="14617,14661" type="NonOSE_AE">
      <Normalization meddra_llt="Angioedema of larynx" meddra_llt_id="10002427" meddra_pt="Angioedema" meddra_pt_id="10002424" />
    </Mention>
    <Mention id="M256" len="18" reason="manifestation_or_complication" section="S3" start="14669" type="NonOSE_AE">
      <Normalization meddra_llt="Airway obstruction NOS" meddra_llt_id="10001536" meddra_pt="Obstructive airways disorder" meddra_pt_id="10061877" />
    </Mention>
    <Mention id="M272" len="21" reason="AE_only_as_instruction" section="S3" start="14723" type="NonOSE_AE">
      <Normalization meddra_llt="Anaphylactic reaction" meddra_llt_id="10002198" meddra_pt="Anaphylactic reaction" meddra_pt_id="10002198" />
    </Mention>
    <Mention id="M273" len="10" reason="AE_only_as_instruction" section="S3" start="14761" type="NonOSE_AE">
      <Normalization meddra_llt="Angioedema" meddra_llt_id="10002424" meddra_pt="Angioedema" meddra_pt_id="10002424" />
    </Mention>
    <Mention id="M258" len="23" reason="AE_only_as_instruction" section="S3" start="15095" type="NonOSE_AE">
      <Normalization meddra_llt="Endometrial hyperplasia" meddra_llt_id="10014755" meddra_pt="Endometrial hyperplasia" meddra_pt_id="10014755" />
    </Mention>
    <Mention id="M259" len="23" reason="AE_only_as_instruction" section="S3" start="15170" type="NonOSE_AE">
      <Normalization meddra_llt="Endometrial hyperplasia" meddra_llt_id="10014755" meddra_pt="Endometrial hyperplasia" meddra_pt_id="10014755" />
    </Mention>
    <Mention id="M260" len="18" reason="AE_only_as_instruction" section="S3" start="15216" type="NonOSE_AE">
      <Normalization meddra_llt="Endometrial cancer" meddra_llt_id="10014733" meddra_pt="Endometrial cancer" meddra_pt_id="10014733" />
    </Mention>
    <Mention id="M261" len="13" reason="AE_from_drug_interaction" section="S3" start="15410" type="NonOSE_AE">
      <Normalization meddra_llt="Breast cancer" meddra_llt_id="10006187" meddra_pt="Breast cancer" meddra_pt_id="10006187" />
    </Mention>
    <Mention id="M301" len="27" reason="class_effect" section="S3" start="15508" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rise in blood pressure" meddra_llt_id="10039196" meddra_pt="Blood pressure increased" meddra_pt_id="10005750" />
    </Mention>
    <Mention id="M184" len="20" reason="preexisting_condition_or_risk_factor" section="S3" start="15791" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hypertriglyceridemia" meddra_llt_id="10020870" meddra_pt="Hypertriglyceridaemia" meddra_pt_id="10020869" />
    </Mention>
    <Mention id="M302" len="34" reason="class_effect" section="S3" start="15853" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Plasma triglycerides increased" meddra_llt_id="10035456" meddra_pt="Blood triglycerides increased" meddra_pt_id="10005839" />
    </Mention>
    <Mention id="M262" len="12" reason="manifestation_or_complication" section="S3" start="15899" type="NonOSE_AE">
      <Normalization meddra_llt="Pancreatitis" meddra_llt_id="10033645" meddra_pt="Pancreatitis" meddra_pt_id="10033645" />
    </Mention>
    <Mention id="M263" len="12" reason="AE_only_as_instruction" section="S3" start="15954" type="NonOSE_AE">
      <Normalization meddra_llt="Pancreatitis" meddra_llt_id="10033645" meddra_pt="Pancreatitis" meddra_pt_id="10033645" />
    </Mention>
    <Mention id="M185" len="23" reason="preexisting_condition_or_risk_factor" section="S3" start="16104" type="Not_AE_Candidate">
      <Normalization meddra_llt="Impaired liver function" meddra_llt_id="10021520" meddra_pt="Hepatic function abnormal" meddra_pt_id="10019670" />
    </Mention>
    <Mention id="M186" len="20" reason="preexisting_condition_or_risk_factor" section="S3" start="16157" type="Not_AE_Candidate">
      <Normalization meddra_llt="Cholestatic jaundice" meddra_llt_id="10008640" meddra_pt="Jaundice cholestatic" meddra_pt_id="10023129" />
    </Mention>
    <Mention id="M187" len="9" reason="preexisting_condition_or_risk_factor" section="S3" start="16220" type="Not_AE_Candidate">
      <Normalization meddra_llt="Pregnancy" meddra_llt_id="10036556" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M303" len="47" reason="class_effect" section="S3" start="16387" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thyroid binding globulin increased" meddra_llt_id="10043698" meddra_pt="Thyroxin binding globulin increased" meddra_pt_id="10051420" />
    </Mention>
    <Mention id="M274" len="13" reason="AE_only_as_instruction" section="S3" start="16494" type="NonOSE_AE">
      <Normalization meddra_llt="Thyroxin binding globulin increased" meddra_llt_id="10051420" meddra_pt="Thyroxin binding globulin increased" meddra_pt_id="10051420" />
    </Mention>
    <Mention id="M304" len="15" reason="class_effect" section="S3" start="16966" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fluid retention" meddra_llt_id="10016807" meddra_pt="Fluid retention" meddra_pt_id="10016807" />
    </Mention>
    <Mention id="M188" len="7,11" reason="preexisting_condition_or_risk_factor" section="S3" start="17054,17071" type="Not_AE_Candidate">
      <Normalization meddra_llt="Cardiac dysfunction" meddra_llt_id="10079751" meddra_pt="Cardiac dysfunction" meddra_pt_id="10079751" />
    </Mention>
    <Mention id="M189" len="17" reason="preexisting_condition_or_risk_factor" section="S3" start="17065" type="Not_AE_Candidate">
      <Normalization meddra_llt="Kidney dysfunction" meddra_llt_id="10023417" meddra_pt="Renal impairment" meddra_pt_id="10062237" />
    </Mention>
    <Mention id="M190" len="18" reason="preexisting_condition_or_risk_factor" section="S3" start="17238" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hypoparathyroidism" meddra_llt_id="10021041" meddra_pt="Hypoparathyroidism" meddra_pt_id="10021041" />
    </Mention>
    <Mention id="M314" len="12" reason="class_effect" section="S3" start="17277" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypocalcemia" meddra_llt_id="10020949" meddra_pt="Hypocalcaemia" meddra_pt_id="10020947" />
    </Mention>
    <Mention id="M315" len="33" reason="class_effect" section="S3" start="17360" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Angioedema" meddra_llt_id="10002424" meddra_pt="Angioedema" meddra_pt_id="10002424" />
    </Mention>
    <Mention id="M191" len="21" reason="preexisting_condition_or_risk_factor" section="S3" start="17408" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hereditary angioedema" meddra_llt_id="10019860" meddra_pt="Hereditary angioedema" meddra_pt_id="10019860" />
    </Mention>
    <Mention id="M317" len="29" reason="class_effect" section="S3" start="17441" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Endometriosis" meddra_llt_id="10014778" meddra_pt="Endometriosis" meddra_pt_id="10014778" />
    </Mention>
    <Mention id="M316" len="57" reason="class_effect" section="S3" start="17489" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Malignant transformation" meddra_llt_id="10064912" meddra_pt="Malignant transformation" meddra_pt_id="10064912" />
    </Mention>
    <Mention id="M204" len="13" reason="preexisting_condition_or_risk_factor" section="S3" start="17663" type="Not_AE_Candidate">
      <Normalization meddra_llt="Endometriosis" meddra_llt_id="10014778" meddra_pt="Endometriosis" meddra_pt_id="10014778" />
    </Mention>
    <Mention id="M318" len="22" reason="class_effect" section="S3" start="17820" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Exacerbation of asthma" meddra_llt_id="10015575" meddra_pt="Asthma" meddra_pt_id="10003553" />
    </Mention>
    <Mention id="M319" len="15,17" reason="class_effect" section="S3" start="17820,17844" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diabetes mellitus loss of control" meddra_llt_id="10012610" meddra_pt="Diabetes mellitus inadequate control" meddra_pt_id="10012607" />
    </Mention>
    <Mention id="M320" len="15,8" reason="class_effect" section="S3" start="17820,17863" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Other forms of epilepsy, without mention of intractable epilepsy" meddra_llt_id="10032063" meddra_pt="Epilepsy" meddra_pt_id="10015037" />
    </Mention>
    <Mention id="M321" len="15,8" reason="class_effect" section="S3" start="17820,17873" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Variants of migraine without mention of intractable migraine" meddra_llt_id="10046977" meddra_pt="Migraine" meddra_pt_id="10027599" />
    </Mention>
    <Mention id="M322" len="15,9" reason="class_effect" section="S3" start="17820,17883" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Porphyria" meddra_llt_id="10036181" meddra_pt="Porphyria" meddra_pt_id="10036181" />
    </Mention>
    <Mention id="M323" len="15,28" reason="class_effect" section="S3" start="17820,17894" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Systemic lupus erythematosus" meddra_llt_id="10042945" meddra_pt="Systemic lupus erythematosus" meddra_pt_id="10042945" />
    </Mention>
    <Mention id="M324" len="15,19" reason="class_effect" section="S3" start="17820,17928" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hemangioma of liver" meddra_llt_id="10019396" meddra_pt="Haemangioma of liver" meddra_pt_id="10018821" />
    </Mention>
    <Mention id="M192" len="18" reason="indication" section="S3" start="18177" type="Not_AE_Candidate">
      <Normalization meddra_llt="Imbalance autonomic nervous system" meddra_llt_id="10021405" meddra_pt="Autonomic nervous system imbalance" meddra_pt_id="10003840" />
    </Mention>
    <Mention id="M193" len="6,7" reason="indication" section="S3" start="18231,18250" type="Not_AE_Candidate">
      <Normalization meddra_llt="Vulvovaginitis atrophic" meddra_llt_id="10047795" meddra_pt="Atrophic vulvovaginitis" meddra_pt_id="10003693" />
    </Mention>
    <Mention id="M194" len="15" reason="indication" section="S3" start="18242" type="Not_AE_Candidate">
      <Normalization meddra_llt="Vulvovaginal atrophy" meddra_llt_id="10047782" meddra_pt="Atrophic vulvovaginitis" meddra_pt_id="10003693" />
    </Mention>
    <Mention id="M196" len="15" reason="preexisting_condition_or_risk_factor" section="S3" start="18336" type="Not_AE_Candidate">
      <Normalization meddra_llt="Oestrogen deficiency" meddra_llt_id="10030247" meddra_pt="Oestrogen deficiency" meddra_pt_id="10030247" />
    </Mention>
    <Mention id="M195" len="12" reason="preexisting_condition_or_risk_factor" section="S3" start="18359" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hypogonadism female" meddra_llt_id="10021010" meddra_pt="Hypogonadism female" meddra_pt_id="10021010" />
    </Mention>
    <Mention id="M197" len="23" reason="preexisting_condition_or_risk_factor" section="S3" start="18388" type="Not_AE_Candidate">
      <Normalization meddra_llt="Ovarian failure primary" meddra_llt_id="10033168" meddra_pt="Ovarian failure" meddra_pt_id="10033165" />
    </Mention>
    <Mention id="M325" len="11,25" reason="from_drug_use" section="S3" start="18460,18523" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Platelet aggregation increased" meddra_llt_id="10035518" meddra_pt="Platelet aggregation increased" meddra_pt_id="10035518" />
    </Mention>
    <Mention id="M326" len="11,27" reason="from_drug_use" section="S3" start="18460,18490" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Partial thromboplastin time shortened" meddra_llt_id="10075335" meddra_pt="Activated partial thromboplastin time shortened" meddra_pt_id="10000637" />
    </Mention>
    <Mention id="M327" len="28" reason="from_drug_use" section="S3" start="18460" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Prothrombin time decreased" meddra_llt_id="10037059" meddra_pt="Prothrombin time shortened" meddra_pt_id="10037070" />
    </Mention>
    <Mention id="M328" len="24" reason="from_drug_use" section="S3" start="18550" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Platelet count increased" meddra_llt_id="10051608" meddra_pt="Platelet count increased" meddra_pt_id="10051608" />
    </Mention>
    <Mention id="M329" len="9,20" reason="from_drug_use" section="S3" start="18576,18699" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Coagulation factor increased" meddra_llt_id="10009743" meddra_pt="Coagulation factor increased" meddra_pt_id="10009743" />
    </Mention>
    <Mention id="M330" len="9,2,1,13" reason="from_drug_use" section="S3" start="18576,18594,18665,18680" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Coagulation factor increased" meddra_llt_id="10009743" meddra_pt="Coagulation factor increased" meddra_pt_id="10009743" />
    </Mention>
    <Mention id="M331" len="9,3,10" reason="from_drug_use" section="S3" start="18576,18598,18665" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Coagulation factor increased" meddra_llt_id="10009743" meddra_pt="Coagulation factor increased" meddra_pt_id="10009743" />
    </Mention>
    <Mention id="M332" len="16,3" reason="from_drug_use" section="S3" start="18576,18657" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Coagulation factor XII level increased" meddra_llt_id="10009784" meddra_pt="Coagulation factor XII level increased" meddra_pt_id="10009784" />
    </Mention>
    <Mention id="M333" len="16,1" reason="from_drug_use" section="S3" start="18576,18651" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Coagulation factor X level increased" meddra_llt_id="10009776" meddra_pt="Coagulation factor X level increased" meddra_pt_id="10009776" />
    </Mention>
    <Mention id="M334" len="16,2" reason="from_drug_use" section="S3" start="18576,18650" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Coagulation factor IX level increased" meddra_llt_id="10009748" meddra_pt="Coagulation factor IX level increased" meddra_pt_id="10009748" />
    </Mention>
    <Mention id="M335" len="16,4,18" reason="from_drug_use" section="S3" start="18576,18611,18630" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Coagulation factor VIII level increased" meddra_llt_id="10009770" meddra_pt="Coagulation factor VIII level increased" meddra_pt_id="10009770" />
    </Mention>
    <Mention id="M336" len="16,12" reason="from_drug_use" section="S3" start="18576,18611" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Coagulation factor VIII level increased" meddra_llt_id="10009770" meddra_pt="Coagulation factor VIII level increased" meddra_pt_id="10009770" />
    </Mention>
    <Mention id="M337" len="16,11" reason="from_drug_use" section="S3" start="18576,18598" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Coagulation factor VII level increased" meddra_llt_id="10009763" meddra_pt="Coagulation factor VII level increased" meddra_pt_id="10009763" />
    </Mention>
    <Mention id="M338" len="16,2" reason="from_drug_use" section="S3" start="18576,18594" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Coagulation factor II level increased" meddra_llt_id="10009741" meddra_pt="Prothrombin level increased" meddra_pt_id="10037051" />
    </Mention>
    <Mention id="M339" len="19,16" reason="from_drug_use" section="S3" start="18721,18759" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Antithrombin III decreased" meddra_llt_id="10049547" meddra_pt="Antithrombin III decreased" meddra_pt_id="10049547" />
    </Mention>
    <Mention id="M340" len="33" reason="from_drug_use" section="S3" start="18721" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anti factor Xa activity decreased" meddra_llt_id="10078931" meddra_pt="Anti factor Xa activity decreased" meddra_pt_id="10078931" />
    </Mention>
    <Mention id="M341" len="35" reason="from_drug_use" section="S3" start="18777" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Antithrombin III decreased" meddra_llt_id="10049547" meddra_pt="Antithrombin III decreased" meddra_pt_id="10049547" />
    </Mention>
    <Mention id="M342" len="9,10,8" reason="from_drug_use" section="S3" start="18814,18834,18860" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fibrinogen increased" meddra_llt_id="10016597" meddra_pt="Blood fibrinogen increased" meddra_pt_id="10005521" />
    </Mention>
    <Mention id="M343" len="30" reason="from_drug_use" section="S3" start="18814" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fibrinogen increased" meddra_llt_id="10016597" meddra_pt="Blood fibrinogen increased" meddra_pt_id="10005521" />
    </Mention>
    <Mention id="M344" len="21,8" reason="from_drug_use" section="S3" start="18870,18904" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Plasminogen activity increased" meddra_llt_id="10035492" meddra_pt="Plasminogen increased" meddra_pt_id="10035495" />
    </Mention>
    <Mention id="M345" len="29" reason="from_drug_use" section="S3" start="18870" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Plasminogen increased" meddra_llt_id="10035495" meddra_pt="Plasminogen increased" meddra_pt_id="10035495" />
    </Mention>
    <Mention id="M346" len="47" reason="from_drug_use" section="S3" start="18916" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thyroid binding globulin increased" meddra_llt_id="10043698" meddra_pt="Thyroxin binding globulin increased" meddra_pt_id="10051420" />
    </Mention>
    <Mention id="M264" len="50" reason="manifestation_or_complication" section="S3" start="18975" type="NonOSE_AE">
      <Normalization meddra_llt="Thyroid stimulating hormone increased" meddra_llt_id="10043770" meddra_pt="Blood thyroid stimulating hormone increased" meddra_pt_id="10005833" />
    </Mention>
    <Mention id="M347" len="27" reason="from_drug_use" section="S3" start="19146" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tri-iodothyronine uptake decreased" meddra_llt_id="10044601" meddra_pt="Tri-iodothyronine uptake decreased" meddra_pt_id="10044601" />
    </Mention>
    <Mention id="M275" len="12" reason="manifestation_or_complication" section="S3" start="19190" type="NonOSE_AE">
      <Normalization meddra_llt="Thyroxin binding globulin increased" meddra_llt_id="10051420" meddra_pt="Thyroxin binding globulin increased" meddra_pt_id="10051420" />
    </Mention>
    <Mention id="M348" len="8,36" reason="from_drug_use" section="S3" start="19366,19398" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Corticosteroid binding globulin increased" meddra_llt_id="10072935" meddra_pt="Corticosteroid binding globulin increased" meddra_pt_id="10072935" />
    </Mention>
    <Mention id="M349" len="8,34" reason="from_drug_use" section="S3" start="19366,19437" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sex hormone binding globulin increased" meddra_llt_id="10059659" meddra_pt="Sex hormone binding globulin increased" meddra_pt_id="10059659" />
    </Mention>
    <Mention id="M265" len="60" reason="manifestation_or_complication" section="S3" start="19485" type="NonOSE_AE">
      <Normalization meddra_llt="Increased steroid activity" meddra_llt_id="10021684" meddra_pt="Increased steroid activity" meddra_pt_id="10021684" />
    </Mention>
    <Mention id="M350" len="12,9" reason="from_drug_use" section="S3" start="19598,19633" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Testosterone decreased" meddra_llt_id="10043368" meddra_pt="Blood testosterone decreased" meddra_pt_id="10005814" />
    </Mention>
    <Mention id="M351" len="9,9" reason="from_drug_use" section="S3" start="19615,19633" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Estradiol decreased" meddra_llt_id="10054509" meddra_pt="Oestradiol decreased" meddra_pt_id="10030229" />
    </Mention>
    <Mention id="M352" len="9,13" reason="from_drug_use" section="S3" start="19673,19738" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ceruloplasmin increased" meddra_llt_id="10008219" meddra_pt="Ceruloplasmin increased" meddra_pt_id="10008219" />
    </Mention>
    <Mention id="M353" len="9,19" reason="from_drug_use" section="S3" start="19673,19717" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Alpha-1 anti-trypsin increased" meddra_llt_id="10001808" meddra_pt="Alpha-1 anti-trypsin increased" meddra_pt_id="10001808" />
    </Mention>
    <Mention id="M354" len="9,15" reason="from_drug_use" section="S3" start="19673,19700" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Renin increased" meddra_llt_id="10038559" meddra_pt="Renin increased" meddra_pt_id="10038559" />
    </Mention>
    <Mention id="M355" len="9,15" reason="from_drug_use" section="S3" start="19673,19684" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Angiotensin I increased" meddra_llt_id="10002488" meddra_pt="Angiotensin I increased" meddra_pt_id="10002488" />
    </Mention>
    <Mention id="M356" len="46" reason="from_drug_use" section="S3" start="19756" type="OSE_Labeled_AE">
      <Normalization meddra_llt="High density lipoprotein increased" meddra_llt_id="10020061" meddra_pt="High density lipoprotein increased" meddra_pt_id="10020061" />
    </Mention>
    <Mention id="M357" len="9,42" reason="class_effect" section="S3" start="19756,19808" type="OSE_Labeled_AE">
      <Normalization meddra_llt="HDL2 cholesterol increased" meddra_llt_id="10078994" meddra_pt="High density lipoprotein increased" meddra_pt_id="10020061" />
    </Mention>
    <Mention id="M358" len="64" reason="from_drug_use" section="S3" start="19852" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Low density lipoprotein cholesterol low" meddra_llt_id="10024907" meddra_pt="Low density lipoprotein decreased" meddra_pt_id="10024909" />
    </Mention>
    <Mention id="M359" len="29" reason="from_drug_use" section="S3" start="19918" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Triglyceride increased" meddra_llt_id="10044659" meddra_pt="Blood triglycerides increased" meddra_pt_id="10005839" />
    </Mention>
    <Mention id="M360" len="26" reason="from_drug_use" section="S3" start="19951" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Glucose tolerance impaired" meddra_llt_id="10018429" meddra_pt="Glucose tolerance impaired" meddra_pt_id="10018429" />
    </Mention>
  </Mentions>
</GoldLabel>